Abstract: Polysaccharide based hydrogel compositions and methods of making and using the same are provided. The subject polysaccharide based hydrogel compositions are prepared by combining a polysaccharide component with a hydrophilic polymer and a cross-linking agent. Also provided are kits and systems for use in preparing the subject compositions.

Title: POLYSACCHARIDE BASED HYDROGELS
POLYSACCHARIDE BASED HYDROGELS

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. provisional Application No. 61/259,564, filed on November 9, 2009, which is herein incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

Hydrogels are water-swollen networks of hydrophilic homopolymers or copolymers. These networks may be formed by various techniques; however, the most common synthetic route is the free radical polymerization of vinyl monomers in the presence of a difunctional cross-linking agent and a swelling agent. The resulting polymer exhibits both liquid-like properties, attributable to the major constituent, water, and solid-like properties due to the network formed by the cross-linking reaction. These solid-like properties take the form of a shear modulus that is evident upon deformation.

Hydrogels offer biocompatibility and have been shown to have reduced tendency for inducing thrombosis, encrustation and inflammation when used in medical devices. Unfortunately, the use of hydrogels in biomedical device applications has been hindered by poor mechanical performance. Many medical devices use hydrogels to improve device biocompatibility; however, many hydrogels can only be used in coatings as a result of insufficient mechanical performance for use as a bulk polymer. Many hydrogels suffer from low modulus, low yield stress, and low strength when compared to non-swollen polymer systems. Lower mechanical properties result from the swollen nature of hydrogels and the non-stress bearing nature of the swelling agent.

The state of the art hydrogel formulations do not adequately bind to all types of tissue surfaces. Furthermore, many of the existing hydrogel materials are not consistent in their ability to provide hemostatic control. The potency of these materials is limited by addressing one of the many qualities that are desirable in a hydrogel biomaterial (e.g. hemostasis or acting as an adhesion barrier, or providing infection control, or eliciting a minimal tissue response). A hydrogel biomaterial that addresses these multiple qualities consistently is not currently available in the art.

As such, there is a continuing need to develop new compositions capable of forming biocompatible hydrogel structures that offer improved therapeutic outcomes.
SUMMARY OF THE INVENTION

Polysaccharide based hydrogel compositions and methods of making and using the same are provided. The subject polysaccharide based hydrogel compositions are prepared by combining a polysaccharide component with a hydrophilic polymer and a cross-linking agent. Also provided are kits and systems for use in preparing the subject compositions.

These and other objects, advantages, and features of the invention will become apparent to those persons skilled in the art upon reading the details of the disclosure as more fully described below.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention is best understood from the following detailed description when read in conjunction with the accompanying drawings. It is emphasized that, according to common practice, the various features of the drawings are not to-scale. On the contrary, the dimensions of the various features are arbitrarily expanded or reduced for clarity.

Included in the drawings are the following figures.

FIG. 1 shows a matrix of an exemplary polysaccharide based hydrogel.
FIG. 2 shows the chemical structure for PEG Succinimidyl Succinate.

FIG. 3 shows the chemical structure for PEG Succinimidyl Glutarate.

FIG. 4 shows an exemplary composition of a PEG-PEG-Chitosan hydrogel.

FIG. 5 shows an exemplary composition of a PEG-GA-Chitosan hydrogel.

FIG. 6 shows an exemplary composition of a PEG-PEG-carboxymethylcellulose hydrogel.

FIG. 7 shows an exemplary composition of a PEG-PEG-chitosan hydrogel cryomilled into a particulate form.

FIG. 8 shows an exemplary composition of a freeze-dried PEG-PEG-chitosan hydrogel rolled into a tube and held by a pair of forceps.

FIG. 9 shows an exemplary composition of a shape-memory embodiment of a PEG-PEG-chitosan hydrogel in the dry and hydrated states.

FIG. 10 shows an exemplary composition of a PEG-PEG-chitosan hydrogel applied as a spray in a thin coating to a human palm.

FIG. 11 shows a cross-sectional view of a bovine tendon coated with an exemplary composition of a PEG-PEG-chitosan hydrogel.

FIG. 12 shows a perspective view of a spray coating of an exemplary composition of a PEG-glutaraldehyde-chitosan hydrogel applied to a human hand.

FIG. 13 shows a cross-sectional view of an exemplary composition of a freeze-dried PEG-PEG-chitosan hydrogel coated with an exemplary composition of a PEG-PEG-chitosan hydrogel.

FIG. 14 shows a cross-sectional view of an exemplary composition of a freeze-dried PEG-PEG-chitosan hydrogel coated with an exemplary composition of a PEG-PEG-chitosan hydrogel doubled on itself and held in a pair of forceps.

FIG. 15 shows a hollow chamber formed from an exemplary composition of a PEG-PEG-chitosan hydrogel.

DETAILED DESCRIPTION OF THE INVENTION

Before the present invention is described, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise,
between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[0031] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, some potential and preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. It is understood that the present disclosure supersedes any disclosure of an incorporated publication to the extent there is a contradiction.

[0032] It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a compound" includes a plurality of such compounds and reference to "the polymer" includes reference to one or more polymer and equivalents thereof known to those skilled in the art, and so forth.

[0033] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

**Introduction**

[0034] In general, the present invention includes hydrogel compositions that have been fabricated out of a polysaccharide and two or more additional components. The subject hydrogel compositions are characterized by being capable of bonding tissue in both wet (e.g., blood) and dry environments, where adhesion of the composition to the tissue is physiologically acceptable. A further feature of the subject compositions is that they are
well tolerated and do not elicit a substantial inflammatory response, if any inflammatory response. The subject compositions can provide multiple desirable qualities such as a combination of any of the following: hemostatic properties, adhesive properties, re-vascularization, biocompatibility, bactericidal, bacteriostatic and/or fungicidal properties, tissue remodeling and/or provides a scaffold for tissue engineering, regeneration, and/or cell seeding, enzymatic or hydrolytic degradation pathways, swelling, engineered residence times, engineered viscosities, temperature or energy activation, inclusion of agents to enable visualization under imaging modalities (X-ray, CT, MRI, US, PET, CTA, etc.), engineered degree of hydrophilicity or hydrophobicity, gap and/or space filling, surface coating, ability to absorb energy, inclusion of foaming agents, inclusion of visual agents, ability to act as a drug delivery platform, media for sound transmission, and engineered durometer.

The subject polysaccharide based hydrogel compositions are prepared by combining or mixing a polysaccharide element and two or more components, such as a polymer and a cross-linking agent. An exemplary matrix is provided in FIG. 1. Each of these precursor components or compositions is now reviewed separately in greater detail.

**Compositions**

As noted above, the compositions of the present invention include a polysaccharide component. Examples of polysaccharides suitable for use with the present invention include, but are not limited to, chitosan, hyaluronic acid, the family of chondroitin sulfates, heparin, keratan sulfate, glycogen, glucose, amylase, amylopectin and derivatives thereof. The polysaccharide may be naturally occurring or synthetically produced. Polysaccharides have several reactive groups that are available for chemical modification. These include the hydroxyl (OH), carboxyl (COOH), and acetamido (COCH₃) groups. Further functionality can be imparted to specific polysaccharides in the form of an amine (NH₂) group via basic deacetylation, in which a polysaccharide is exposed to basic conditions at elevated temperatures. The degree of deacetylation is dependent on the strength of the alkaline conditions, the temperature of the reaction environment, and the duration of the reaction. For example, the percentage of deacetylation can be controlled to obtain different chitosan molecules from a single source of chitin. Other methods of imparting functionality onto polysaccharides are known to the art, such as the functionalizing of native hyaluronic acid with amine groups through the use of a hydrazide as taught by Prestwich and Marecak in US Pat. No. 5,874,417, which is herein incorporated by reference. In this method, the carboxyl group
of the disaccharide is linked to a multi-functional hydrazide under acidic conditions in the presence of a soluble carbodiimide.

In certain embodiments, the polysaccharide is chitosan. Chitosan is a disaccharide formed through the deacetylation of chitin, a naturally occurring material found in crustacean shells and some fungi. Chitosan is a biocompatible, hydrophilic polymer with hemostatic and antimicrobial characteristics. The Chitosan may be from a natural occurring source or may be synthetically derived. Chitosan is described in detail is U.S. Patent Nos. 5,836,970, 5,599,916, and 6,444,797, the disclosures of which are incorporated by reference herein in their entirety.

The non-polysaccharide components of the hydrogel material may include a hydrophilic polymer such as any of the following natural, synthetic, or hybrid polymers: poly(ethylene glycol), poly(ethylene oxide), poly(vinyl alcohol), poly(allyl alcohol), poly(vinylpyrrolidone), poly(alkylene oxides), poly(oxyethylated polyols), poly(ethyleneimine), poly(allylamine), poly(vinyl amine), poly(aminocids), poly(ethyloxazoline), poly(ethylene oxide)-co-poly(propylene oxide) block copolymers, polysaccharides, carbohydrates, oligopeptides, and polypeptides. The polymer chains may include homo-, co-, or terpolymers of the above materials, in a linear or branched form, and derivatives thereof. These materials may crosslink into a hydrogel through the formation of covalent bonds through the action of chemically active groups that are present on the polysaccharide and the counterpart hydrophilic polymers. Among the chemically active groups that are preferred for use in the present invention are those that can form a covalent bond with the readily available nucleophilic or electrophilic residues.

Examples of electrophilic groups that can react with the nucleophilic groups present on component materials include but are not limited to carboxyl groups, isocyanates, thiocyanates, N-hydroxysuccinimide esters, glycidyl ethers, glycidyl epoxides, vinyl sulfones, maleimides, orthopyridyl disulfides, iodoacetamides, and carbodiimides. Examples of nucleophilic groups that can react with the electrophilic groups present on the component materials include but are not limited to anhydrides, primary, secondary, tertiary, or quaternary amines, amides, urethanes, ureas, hydrazides, sulfahydryl groups, or thiols. The preceding list of reactive groups serves as an illustrative example; extension to other nucleophilic and electrophilic moieties should be clear to those of skill in the art.

In one embodiment, the hydrogel composition is a three-component hydrogel that includes a multifunctional PEG with terminal nucleophilic groups, a multifunctional
PEG with terminal electrophilic groups, and chitosan. When the polymeric components are reconstituted with the appropriate buffers and mixed, they react to form a cohesive hydrogel.

[0041] The multifunctional PEG with terminal nucleophilic groups may comprise a difunctionally activated, trifunctionally activated, tetrafunctionally activated, or a star-branched activated polymer. The molecular weight of the multifunctional nucleophilic PEG may be in the range of 1 kiloDalton (kD) to 100 kD; the range of 5 kD to 40 kD; or the range of 10kD to 20kD. The multifunctional nucleophilic PEG mass be present in mass percentages of at least 1%; at least 5%; at least 10%; at least 20%; at least 40%; at least 80%; at least 99%.

[0042] The multifunctional PEG with terminal electrophilic groups may comprise difunctionally activated, trifunctionally activated, tetrafunctionally activated, or a star-branched activated polymer. The molecular weight of the multifunctional electrophilic PEG may be in the range of 1 kD to 100 kD; the range of 5 kD to 40 kD; or the range of 10kD to 20kD. The multifunctional electrophilic PEG mass be present in mass percentages of at least 1%; at least 5%; at least 10%; at least 20%; at least 40%; at least 80%; at least 99%.

[0043] The polysaccharide (e.g., chitosan) may be present in a salt or amine form. The chitosan may have a molecular weight in the range of 10 Dalton to 1kD; the range of 1kD to 10 kD; the range of 10kD to 100 kD; the range of 100 kD to 250 kD; the range of 250 kD to 500 kD; or the range of 500 kD to 1000 kD. The chitosan may have a degree of deacetylation in the range of 1% to 10%; the range of 10% to 20%; the range of 20% to 30%; the range of 30% to 40%; the range of 40% to 50%; the range of 50% to 60%; the range of 60% to 70%; the range of 70% to 80%; the range of 80% to 90%; or the range of 90% to 99%. The chitosan may be present in the set hydrogel in a mass percentage range of 0.1% to 0.1%; a range of 0.1% to 0.5%; a range of 0.5% to 1.0%; a range of 1.0% to 5%; a range of 5% to 10%; a range of 10% to 20%; a range of 20% to 40%; a range of 40% to 80%; or a range of 80% to 99%. In certain embodiments, the polysaccharide is chitosan. In further embodiments, the chitosan may also comprise a derivative of chitosan, such as N,0 carboxymethylchitosan as described in U.S. Pat. No. 5,888,988 the disclosure of which is incorporated herein by reference in its entirety, or a dicarboxyl derivatized chitosan as described in WO 2009/028965 the disclosures of which are incorporated herein by reference in their entirety. For example, dicarboxyl derivatized chitosan may be crosslinked to a polyethylene glycol with at least two
nucleophilic reactive groups via a polyethylene glycol with at least two electrophilic reactive groups.

[0044] Hydrolytically degradable linkages may be incorporated into the backbone of the multifunctional PEG polymers. The inclusion of hydrolytically degradable chemical groups enables the resulting hydrogel to degrade after implantation in a controlled, consistent manner. The chemical groups that border the hydrolytically degradable linkages influence the rate of the hydrolysis reaction. Braunova et al. (Collect. Czech. Chem. Commun. 2004, 69, 1643-1656) have shown that the rate of hydrolysis of ester bonds in poly(ethylene glycol) polymers decreases as the number of methylene groups that border the ester bond is increased. For example, a copolymer of trilysine and a multi-armed poly(ethylene glycol) succinimidyl succinate will degrade in approximately 8 days in aqueous media under physiological conditions. As shown in FIG. 2, the succinimidyl succinate has two methyl groups located next to the hydrolytically susceptible ester bond.

[0045] By way of comparison, a copolymer of trilysine and a multi-armed poly(ethylene glycol) succinimidyl glutarate will degrade in approximately 50 days in aqueous media under physiological conditions. As shown in FIG. 3, the succinimidyl glutarate has three methyl groups located next to the hydrolytically susceptible ester bond.

[0046] As the number of methyl groups neighboring the ester bond increases, the rate of hydrolysis of the ester bond decreases. Further decreases in the rate of hydrolysis of the ester bond should be attained by increasing the number of methyl groups in the PEG polymer along the following progression: PEG succinimidyl adipate, PEG succinimidyl pimelate, PEG succinimidyl suberate, PEG succinimidyl azelate, PEG succinimidyl sebacate, etc. The extension of this method of controlling degradation times to other systems should be readily accessible to one of skill in the art.

[0047] Another form of the invention is a three-component hydrogel comprised of a multifunctional PEG with terminal nucleophilic groups, an aldehyde component, and chitosan. When the polymeric components are reconstituted with the appropriate buffers and mixed, they react to form a cohesive hydrogel.

[0048] The nucleophilic PEG and polysaccharide (e.g., chitosan) components in the composition are as described earlier. The aldehyde component in the composition as provided herein can be any biocompatible aldehyde with low toxicity. In particular, the aldehyde component includes a di-aldehyde, a polyaldehyde or a mixture thereof. The examples of the aldehyde include, but are not limited to, glyoxal, chondroitin sulfate aldehyde, succinaldehyde, glutaraldehyde, and malealdehyde. In some embodiments, the
aldehyde component is glutaraldehyde. Other suitable aldehydes which have low toxicity include multifunctional aldehydes derived from naturally-occurring substances, e.g., dextran dialdehyde, or saccharides. The aldehyde component can be an aldehyde product obtained by an oxidative cleavage of carbohydrates and their derivatives with periodate, ozone or the like. The aldehyde may optionally be pre-treated with heat. See U.S. Pat. No. 7,303,757 by Schankereli for "Biocompatible phase invertable proteinaceous compositions and methods for making and using the same". The aldehyde component can be analyzed for properties such as, viscosity, and osmolality. The aldehyde component of an adhesive composition can itself be further comprised of components and/or sub-components. Thus, the aldehyde component can be described in terms of weight, weight-to-weight, weight-to-volume, or volume-to-volume, either before or after mixing. For example, a polysaccharide may be crosslinked to a multifunctional synthetic polymer with at least two reactive nucleophilic groups via a dextran derivatized with aldehyde groups.

In some embodiments, the aldehyde component comprises of about 1-90% aldehyde concentration. In some embodiments, the aldehyde component comprises of about 1-75% aldehyde concentration. In some embodiments, the aldehyde component comprises of about 5-75% aldehyde concentration; about 10-75% aldehyde concentration; about 20-75% aldehyde concentration; about 30-75% aldehyde concentration; about 40-75% aldehyde concentration; about 50-75% aldehyde concentration; or about 60-75% aldehyde concentration.

The composition can comprise at least about 1% aldehyde concentration; at least about 5% aldehyde concentration; at least about 10% aldehyde concentration; at least about 20% aldehyde concentration; at least about 30% aldehyde concentration; at least about 40% aldehyde concentration; at least about 50% aldehyde concentration; at least about 60% aldehyde concentration; at least about 70% aldehyde concentration; at least about 80% aldehyde concentration; at least about 90% aldehyde concentration; or at least about 99% aldehyde concentration. In some embodiments, the adhesive composition comprises of about 1-30%, about 25-75%, about 50-75% or about 75-99% aldehyde concentration.

In some embodiments, the composition comprises of at least about 1% glutaraldehyde concentration; at least about 5% glutaraldehyde concentration; at least about 8% glutaraldehyde concentration; at least about 10% glutaraldehyde concentration; at least about 20% glutaraldehyde concentration; at least about 30% glutaraldehyde concentration; at least about 40% glutaraldehyde concentration; at least about 50%
glutaraldehyde concentration; at least about 60% glutaraldehyde concentration; at least about 70% glutaraldehyde concentration; at least about 80% glutaraldehyde concentration; at least about 90% glutaraldehyde concentration; or at least about 99% glutaraldehyde concentration. In some embodiments, the composition comprises about 1-30%, about 25-75%, about 50-75% or about 75-99% glutaraldehyde concentration.

Thickening agents may be added to the forms of the invention described above. The thickening agents include, for example, dextran, carboxymethyl cellulose, polyethylene glycol, liposomes, proliposomes, glycerol, starch, carbohydrates, povidone, polyethylene oxide, and polyvinyl alcohol. In some embodiments, the thickening agent is dextran, polyethylene glycol or carboxymethyl cellulose. In some embodiments, the composition comprises at least about 1% thickening agent concentration; at least about 5% thickening agent concentration; at least about 10% thickening agent concentration; at least about 20% thickening agent concentration; at least about 30% thickening agent concentration; at least about 40% thickening agent concentration; at least about 50% thickening agent concentration; at least about 60% thickening agent concentration; at least about 70% thickening agent concentration; at least about 80% thickening agent concentration; or at least about 90% thickening agent concentration. In some embodiments, the composition comprises at least about 0.5%-10%, at least about 0.5%-25%, or at least about 0.5%-50% thickening agent concentration. In some embodiments, the thickening agent can comprise at least about 0.5% of the composition. The thickening agent can alter a gel time of the composition.

Some embodiments of the aforementioned aspects of the present invention may further comprise a radiopaque material. The radiopaque material includes, for example, bismuth oxide (Bi₂O₃), zinc oxide (ZnO), barium sulfate (BaSO₄), lanthanum oxide (La₂O₃), cerium oxide (CeO₂), terbium oxide, ytterbium oxide, neodymium oxide, zirconia (ZrO₂), strontia (SrO), tin oxide (SnO₂), radiopaque glass and silicate glass. The radiopaque glass includes, for example, barium silicate, silico-alumino barium or strontium containing glass. The silicate glass includes, for example, barium or strontium containing glass. In some embodiments, the radiopaque material comprises at least about 0.001%; at least about 0.05%; at least about 0.1%; at least about 0.2%; at least about 0.5%; at least about 1%; at least about 2%; at least about 5%; at least about 8%; or at least about 10% of the adhesive composition.

The hydrogel compositions as provided herein can optionally contain a variety of naturally occurring or synthetically produced additives such as, but not limited to, water, buffer, saline solution, neutral salt, carbohydrate, fiber, miscellaneous biological
material, wetting agent, antibiotics, preservative, dye, thickening agent, thinning agent, fibrinogen, polymer such as polyethylene glycol or combination thereof. Polymers include synthetic polymers such as, polyamides, polyesters, polystyrenes, polycrylates, vinyl polymers (e.g., polyethylene, polytetrafluoro-ethylene, polypropylene and polyvinyl chloride), polycarbonates, polyurethanes, poly dimethyl siloxanes, cellulose acetates, polymethyl methacrylates, ethylene vinyl acetates, polysulfones, nitrocelluloses and similar copolymers. Polymers further include biological polymers which can be naturally occurring or produced in vitro by fermentation and the like. Biological polymers include, without limitation, collagen, elastin, silk, keratin, gelatin, polyamino acids, polysaccharides (e.g., cellulose and starch) and copolymers thereof.

Flexibilizers can be included in the hydrogel composition to provide flexibility to the material bond upon curing. Flexibilizers may be naturally occurring compositions or synthetically produced. Suitable flexibilizers include synthetic and natural rubbers, synthetic polymers, natural non-native biocompatible proteins (such as exogenous (i.e., non-native) collagen and the like), glycosaminoglycans (GAGs) (such as hyaluronan and chondroitin sulfate), and blood components (such as fibrin, fibrinogen, albumin and other blood factors).

The composition as provided herein can optionally include salts and/or buffers. Examples of the salt include, but are not limited to, sodium chloride, potassium chloride and the like. Suitable buffers can include, for example, ammonium, phosphate, borate, bicarbonate, carbonate, cacodylate, citrate, and other organic buffers such as tris(hydroxymethyl) aminomethane (TRIS), morpholine propanesulphonic acid (MOPS), and N-(2-hydroxyethyl) piperazine-N’(2-ethanesulfonic acid) (HEPES). Suitable buffers can be chosen based on the desired pH range for the hydrogel composition.

Additional additives may be present in the formulation to modify the mechanical properties of the composition. Some additives include, for example, fillers, softening agents and stabilizers. Examples of fillers include, but are not limited to, carbon black, metal oxides, silicates, acrylic resin powder, and various ceramic powders. Examples of softening agents include, but are not limited to, dibutyl phosphate, dioctylphosphate, tricresylphosphate, tributoxyethyl phosphates and other esters. Examples of stabilizers include, but are not limited to, trimethylhydroquinone, phenyl-β-naphthyl amine, p-isoproxy diphenylamine, diphenyl-p-phenylene diamine and the like.

One class of additives that may be included in the composition is nanoparticles or nanometer scale constructions. An example of nanoparticles that have been engineered to have specific physical characteristics are nanoshells, as taught by Oldenburg et al. (U.S. Patent No. 7,958,005).
Pat. No. 6,344,272, incorporated herein by reference in its entirety). Nanoshells are comprised of a metallic shell surrounding a non-conducting core; by varying the diameter of the core and the thickness of the shell, the absorption wavelength of the materials can be tuned to specific regions of the spectrum. West et. al. discloses the incorporation of nanoshells into a thermally sensitive polymer matrix for drug delivery in U.S. Pat. Nos. 6,428,811 and 6,645,517, and further teaches the use of nanoshells to treat tumors through localized hyperthermia in U.S. Pat. No. 6,530,994 (the above patents are herein incorporated by reference in their entirety). The combination of nanoparticles or other nanoscale structures with the composition of the invention may provide additional functionality (i.e. tunable absorption spectra) to the composition. In one example, the composition may be employed to fix the nanoparticles tuned to absorb near infrared light in a desired physical position prior to the application of a near-infrared laser to induce local hyperthermia. The incorporation of the nanoshells in the hydrogel matrix prevents the leaching of the nanoshells away from the target area.

The composition may also optionally include a plasticizing agent. The plasticizing agent provides a number of functions, including wetting of a surface, or alternately, increasing the elastic modulus of the material, or further still, aiding in the mixing and application of the material. Numerous plasticizing agents exist, including fatty acids, e.g., oleic acid, palmitic acid, etc., dioctylphthalate, phospholipids, and phosphatidic acid. Because plasticizers are typically water insoluble organic substances and are not readily miscible with water, it is sometimes advantageous to modify their miscibility with water, by pre-mixing the appropriate plasticizer with an alcohol to reduce the surface tension associated with the solution. To this end, any alcohol may be used. In one representative embodiment of this invention, oleic acid is mixed with ethanol to form a 50% (w/w) solution and this solution then is used to plasticize the polymer substrate during the formulation process. Whereas the type and concentration of the plasticizing agent is dependent upon the application, in certain embodiments the final concentration of the plasticizing agent is from about .01 to 10 % (w/w), including from about 2 to about 4 % (w/w). Other plasticizing agents of interest include, but are not limited to: polyethylene glycol, glycerin, butylhydroxytoluene, etc.

Fillers of interest may include both reinforcing and non-reinforcing fillers. Reinforcing fillers may be included, such as chopped fibrous silk, polyester, PTFE, NYLON, carbon fibers, polypropylene, polyurethane, glass, etc. Fibers can be modified, e.g., as described above for the other components, as desired, e.g., to increase wettability, mixability, etc. Reinforcing fillers may be present from about 0 to 40%, such as from
about 10 to about 30%. Non-reinforcing fillers may also be included, e.g., clay, mica, hydroxyapatite, calcium sulfate, bone chips, etc. Where desired, these fillers may also be modified, e.g., as described above. Non-reinforcing fillers may be present from about 0 to 40%, such as from about 10 to about 30%.

[0061] In certain embodiments, the composition may include a foaming agent which, upon combination with the crosslinker composition, results in a foaming composition, e.g., a composition that includes gaseous air bubbles interspersed about. Any convenient foaming agent may be present, where the foaming agent may be an agent that, upon contact with the crosslinking composition, produces a gas that provides bubble generation and, hence, the desired foaming characteristics of the composition. For example, a salt such as sodium bicarbonate in an amount ranging from about 2 to about 5% w/w may be present in the substrate. Upon combination of the substrate with an acidic crosslinker composition, e.g., having a pH of about 5, a foaming composition is produced.

[0062] Biologically active agents may be incorporated into the polymer network of the invention; these agents include but are not limited to naturally occurring or synthetically produced plasma proteins, hormones, enzymes, antibiotics, antiseptic agents, antineoplastic agents, antifungal agents, antiviral agents, anti-inflammatory agents, human and non-human derived growth factors, anesthetics, steroids, cell suspensions, cytotoxins, cell proliferation inhibitors, and biomimetics. The biologically active agents can be incorporated into the hydrogel of the invention by any means known in the art. As a non-limiting example, an agent or multiple agents may be added to the component solutions prior to mixing such that the hydrogel matrix forms around the agent or multiple agents and mechanically encapsulates the agent or agents. Alternatively, the agent or agents may be added to one or all of the component solutions prior to mixing. In another example, the agent or agents may be modified or derivatized to react with the components of the hydrogel and form covalent bonds with the hydrogel. The agent or agents may be bonded to the backbone of the hydrogel structure in a pendant chain configuration or as a fully integrated component of the hydrogel structure. In yet another example, the agent or agents may be suspended within a hydrophobic domain encapsulated within or distributed throughout the hydrogel. Alternatively, the agent or agents may be associated with the backbone of hydrogel through electrostatic, van Der Walls, or hydrophobic interactions. Combinations of any of the aforementioned techniques are also contemplated (e.g., a negatively charged agent that is physically
encapsulated in a positively charged hydrogel matrix). The exact means of incorporation will be dictated by the nature of the biologically active agent.

**Methods**

[0063] Aqueous solutions of the component polymers are mixed to form the hydrogel of the invention. Generally, equal volumes of the aqueous component solutions are mixed to form the hydrogel. However, different ratios of the aqueous component solutions may be used provided the properties of the solutions are such that they crosslink to form the hydrogel of the invention when mixed. A person skilled in the art can achieve different curing times for the hydrogel of the invention by manipulating one or more of the following exemplary parameters:

a) the degree of deacetylation of the polysaccharide (e.g., chitosan);
b) the molecular weight of the polysaccharide (e.g., chitosan);
c) the species of the aldehyde component of the invention;
d) the mass percentage of the polymer components in the aqueous solutions;
e) the relative mass percentage of the respective polymer components in the aqueous solutions;
f) the molecular weight of the multifunctional nucleophilic PEG polymer;
g) the number of arms of the multifunctional nucleophilic PEG polymer;
h) the type of nucleophilic chemical groups resident on the multifunctional nucleophilic PEG polymer;
i) the molecular weight of the multifunctional electrophilic PEG polymer;
j) the number of arms of the multifunctional electrophilic PEG polymer;
k) the type of electrophilic chemical groups resident on the multifunctional electrophilic PEG polymer;
l) the concentration of buffer salts in the aqueous solutions;
m) the pH of the aqueous solutions; and
n) the viscosity of the aqueous solutions.

[0064] In one embodiment of the invention, the hydrogel is formed *in situ*. Aqueous solutions of the invention components can be simultaneously applied or deposited to a target area by spraying, streaming, injecting, painting or pouring of the solutions. The components mix upon application to or deposition at the target area and crosslink to form a polymer network. The formation of the polymer network in an aqueous media creates the hydrogel. Alternatively, the components may mix in transit to the target area. This may happen in the air in the case of the aerosolized or spray application, or in the lumen of a delivery device in the case of a streaming or injection delivery. The mixing of the component solutions may be aided by the use of static or active mixing elements in either delivery, such as inclusion of non-reactive elements to assist in mixing of the
components, e.g., beads. Another method of application would be to mix the aqueous component solutions prior to delivery provided the cure time of the hydrogel was appropriately chosen.

The component solutions may be applied or deposited simultaneously to the target area, or in iterative fashion (application of an initial component solution followed by application of a second component solution, etc.). The method of application or deposition may be any described above, furthermore, the various methodologies and devices for performing in situ curing of a multi-component system may be used to apply the materials of the invention.

In another embodiment of the invention, the hydrogel is formed prior to application. The component solutions may be mixed in an appropriate vessel and allowed cure. The cured hydrogel may then be removed from the vessel and applied to the target area. Alternatively, the cured hydrogel may be dried prior to application to the target area. The term “drying” refers to any process by which the water content of a candidate polymer material is reduced from an initial value to a lower value. This may be accomplished by placing the material in an environment with lower water content than the polymer material under various temperature and pressure conditions, some of which are listed in Table 1.

Table 1:

<table>
<thead>
<tr>
<th>Temperature</th>
<th>Pressure</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ambient</td>
<td>Ambient</td>
<td>Air drying</td>
</tr>
<tr>
<td>Elevated</td>
<td>Ambient</td>
<td>Oven drying</td>
</tr>
<tr>
<td>Ambient</td>
<td>Negative</td>
<td>Vacuum drying</td>
</tr>
<tr>
<td>Elevated</td>
<td>Negative</td>
<td>Vacuum oven drying</td>
</tr>
<tr>
<td>Reduced</td>
<td>Negative</td>
<td>Freeze drying</td>
</tr>
</tbody>
</table>

Application of drying techniques beyond those listed herein should be readily accessible to one of skill in the art. For example, US. Published Pat. App. No. 2007/0231366 teaches a method of drying a hydrogel that comprises halting a solution of components undergoing crosslinking reaction prior to the completion of the reaction by reducing the temperature of the solution below the freezing point of the reacting solution, then subsequently freeze drying the partially-crosslinked hydrogel to remove the solvent.
from the partially crosslinked hydrogel. The partially crosslinked hydrogel is then processed through a series of treatments that serve to complete the crosslinking reaction. The reliance of this method of fabrication on a phase change between liquid and solid is cumbersome, and places limits on the production methods that can be employed in fabricated hydrogels by the taught method. For example, the timing of the transition of the solution from a liquid to solid state (i.e. freezing) is highly dependent on the physical and material characteristics of the mold (wall thickness, heat transfer coefficient, hydrophilicity or hydrophobicity of the mold surface), the freezing method (cold plate, freezer, immersion in liquid nitrogen, etc.), and the rate of the crosslinking reaction among others. Maintaining a consistent process in the face of these variables is challenging and can provide an obstacle to the scaled-up production of a hydrogel via the taught method.

One method for reducing the complexity of the process taught in US. Published Pat. App. No. 2007/0231366 is to use a method for halting or slowing the rate of the crosslinking reaction that is not subject to as many parameters as freezing, such as changing the pH of the solution of reacting components to a level that does not support further crosslinking. For example, the reaction rate of a second-order nucleophilic substitution between an N-hydroxysuccinimide and a primary amine accelerates as the pH of the reaction media becomes more alkaline and decelerates as the pH of the reaction media becomes more acidic. Therefore, the addition of an aliquot of an acidic solution at a sufficient molarity and volume to shift the pH of the reacting media to an acidic condition will halt or slow the reaction rate of the nucleophilic substitution. Yet another means of changing the rate of reaction is by changing the ionic strength of the reaction media. The solution of hydrogel components is then ready for freeze drying. The benefit of this novel method is that the alteration of the reaction rate can be conducted while the hydrogel components are in the liquid phase (e.g. at room temperature), and is not dependent on the size, shape, or material of the casting mold. The independence of the method from the aforementioned limitations will improve consistency of batch-to-batch production lots by reducing the complexity and user-dependence of the process steps and lends itself to scale-up production by simplifying the use of larger molds.

The use of drying and other processing techniques (i.e. necking, stretching, machining, cutting, pressing, forming, etc.) can be combined to impart a shape memory characteristic to the formulation. As an example, a mold of the composition may be cast in the shape of a cylindrical tube and subsequently air dried until the moisture content of
the material has reached equilibrium with environment (as determined by mass or other appropriate methods). The dried formulation may then be subjected to a necking process in which the dry hydrogel is heated and stretched to reduce the diameter and increase the length of the cylinder. When cooled to room temperature, the cylinder retains its necked dimensions. Upon absorbing water, the cylinder reverts to its cast length and dimension. The preceding example demonstrates one method of manipulating the formulation to attain a shape memory feature in response to hydration; the extension of this concept to other external stimuli (i.e. pH, ultrasound, radiation, temperature, etc.) should be accessible to one of skill in the art.

In one embodiment of the invention, the polysaccharide and synthetic polymer are dissolved in a neutral or basic buffer. The crosslinker is dissolved in an appropriately pH balanced buffer. The two solutions are combined to allow the formation of a hydrogel network between the polysaccharide, the synthetic polymer, and the crosslinker. The solutions may be mixed as part of the delivery system for use as an in situ crosslinking material via spray or liquid application, or the solutions may be cast into a mold after mixing to produce a hydrogel for subsequent application without further modification, or the resultant hydrogel may be dried and processed as described previously.

In a second embodiment, the polysaccharide and synthetic polymer are dissolved in a neutral or basic buffer along with a visible dye molecule such as methylene blue, blue dextran, FD&C Blue No.1, FD&C Blue No.2, FD&C Green No.3, FD&C Red No.40, FD&C Red No. 3, FD&C Yellow No.5, FD&C Yellow No. 6, among others. The crosslinker is dissolved in an appropriately buffered solution. The solutions are mixed as described above in the prior embodiments to form the hydrogel. The inclusion of the dye material allows the user to ascertain the thickness and/or location of the hydrogel at the site of application. As an example, the dye may be used to infer the thickness of a coating of the hydrogel applied via a spray or aerosol to a tissue surface by observing changes in the intensity of the dye color as the thickness of the coating increases. As another example, the dye may be used to confirm the coverage of a mold or casting form as a step in a manufacturing process. Alternatively, the visible dye is present in solution with the crosslinker. As yet another alternative, one or more dyes may be included in the polysaccharide/synthetic polymer solution and the crosslinker solution. For example, a blue dye may be added to the polysaccharide/synthetic polymer solution and a yellow dye may be added to the crosslinker solution to allow visual confirmation of mixing of the two components, as the combined solutions will have a green color when well mixed.
Permutations of these techniques with different dyes, combinations of dyes, inclusion of dyes in one or both of the polysaccharide/synthetic polymer solutions, and the like to will be clear to one of skill in the art.

[0072] In a third embodiment, a radio-opaque material may be included with the polysaccharide and synthetic polymer in a neutral or basic buffer. Alternatively, the radio-opaque material may be included with the buffered crosslinker solution, or the radio-opaque material may be included in both the polysaccharide/synthetic polymer solution and the crosslinker solution. The solutions are mixed as described above in the prior embodiments to form a hydrogel that comprises a radio-opaque element dispersed within the body of the hydrogel. The presence of the radio-opaque element allows the visualization of the hydrogel via fluoroscopy when a direct line of sight (i.e. direct visualization) to the hydrogel is not available. For example, an in-situ crosslinking embodiment of the invention may be delivered to a patient through a standard cardiovascular catheter as an embolic agent for the occlusion of uterine fibroids. The location of the hydrogel may be observed as a dark or opaque mass on the output of a fluoroscopic imaging system.

[0073] In a fourth embodiment, a thickening agent may be added to either the neutral to basic solution of polysaccharide and synthetic polymer, the buffered crosslinker solution, or both solutions. The two solutions are combined to initiate the crosslinking reaction and form the hydrogel as described for prior embodiments. The thickening agent may be chosen such that it does not comprise chemical groups that will react with any or all of the polysaccharide, synthetic polymer, or crosslinker components. Alternatively, the thickening agent may be monofunctional, in that it comprises a single reactive group that can bind to a complementary chemical group on any or all of the polysaccharide, synthetic polymer or crosslinker components. The presence of the thickening agent serves to increase the viscosity of one or both of the polysaccharide/synthetic polymer and crosslinker solutions. As an example, a thickening agent may be added to the crosslinker solution if the polysaccharide/synthetic polymer solution is significantly more viscous than the crosslinking solution prior to the addition of the thickening agent. Matching the viscosity of the two component solutions can improve the mixing of the solutions to produce a more consistent, homogenous hydrogel structure and reduce variability that may be present in the rate of the crosslinking reaction due to incomplete or inefficient mixing among other improvements in handling. As another example, a thickening agent may be added to either or both of the polysaccharide/synthetic polymer and crosslinker solutions to produce a solution that resists migration from the point of
delivery prior to complete crosslinking and formation of the hydrogel. In an exemplary case of the delivery of an in-situ crosslinking embodiment of the hydrogel, a highly viscous material will not be washed away, diffused, or otherwise diluted during the time between delivery and completion of the crosslinking reaction.

[0074] In a fifth embodiment, a steroid may be combined with a crosslinker in a neutral to acidic buffer. The polysaccharide and synthetic polymer are dissolved in a neutral to basic buffer solution. The two solutions are combined to initiate the crosslinking reaction and form the hydrogel as described for prior embodiments, entrapping the steroid in the hydrogel network. Steroids are generally insoluble in basic or alkaline solutions, therefore the addition of a steroid to the neutral to acidic buffer containing the crosslinker acts to prevent or mitigate the precipitation of the steroid out of solution prior to the full incorporation of the steroid into the hydrogel. Upon application to a wound, or implantation into a subject, the steroid will either diffuse out of the hydrogel at a rate dictated in part by the pore size of the hydrogel, or it will remain entrapped in the hydrogel until the hydrogel degrades to a point that allows for diffusion of the steroid into the surrounding anatomy.

[0075] In a sixth embodiment, an antibiotic such as gentamicin may be combined with a crosslinker in a neutral to acidic buffer. The polysaccharide and synthetic polymer are dissolved in a neutral to basic buffer solution. The two solutions are combined to initiate the crosslinking reaction and form the hydrogel as described for prior embodiments, entrapping the steroid in the hydrogel network. Antibiotics are generally insoluble in basic or alkaline solutions, therefore the addition of an antibiotic to the neutral to acidic buffer containing the crosslinker acts to prevent or mitigate the precipitation of the antibiotic out of solution prior to the full incorporation of the steroid into the hydrogel. Upon application to a wound, or implantation into a subject, the antibiotic will either diffuse out of the hydrogel at a rate dictated in part by the pore size of the hydrogel, or it will remain entrapped in the hydrogel until the hydrogel degrades to a point that allows for diffusion of the antibiotic into the surrounding anatomy.

[0076] In a seventh embodiment, a fully crosslinked form of the composition of the invention may be used as a carrier for platelet-rich-plasma (PRP). The fully crosslinked form of the hydrogel is submerged into a solution of PRP in a state of less than equilibrium swelling to absorb the PRP into the interstices of the hydrogel network. The fully crosslinked state of the hydrogel may include but is not limited to forms such as an air dried form, a fully cured but not yet dried (semi-hydrated) form, a lyophilized form, and a dried and fragmented form among others. The PRP-loaded composition of the
invention is then applied to a target anatomy, such as a soft tissue defect (e.g. tendon, ligament, hernia, rotator cuff, etc.), a laceration or external wound bed (e.g. pressure sore, diabetic ulcer, etc.), or a hard tissue defect (e.g. bone) to deliver the PRP to the target area over a specified period of time. Alternatively, an external material may be used to absorb and carry the PRP (e.g. gauze sponge, TephaFLEX® knitted monofilament mesh, TephaFLEX® absorbable film, collagen sponge, bandages, other scaffold materials, etc.) with the composition of the invention applied to the surface of the carrier to form a hydrogel coating and act as a barrier to diffusion of the PRP out of the carrier material. Calcium, thrombin or collagen may optionally be added to activate the release of growth factors from the PRP. The method of application may include but is not limited to a spray application, dip-coating, and painting among others.

[0077] It should be clear that the examples of incorporating the steroid, antibiotic, and PRP into the composition of the invention can be extended to any biologically active agent, including but not limited to naturally occurring or synthetically produced plasma proteins, hormones, enzymes, antiseptic agents, antineoplastic agents, antifungal agents, antiviral agents, anti-inflammatory agents, human and non human derived growth factors, anesthetics, cell suspensions, cytotoxins, cell proliferation inhibitors, fibrin, fibrinogen, collagen, and biomimetics.

[0078] In an eighth embodiment, a fiber such as methylcellulose may be added to the composition to prevent adsorption of the material across the gastrointestinal track. Methylcellulose may be added to a solution of fragmented hydrogel in an appropriate buffer for this purpose.

[0079] In a ninth embodiment, a wetting agent such as oleic acid may be added to either the neutral to basic solution of polysaccharide and synthetic polymer, the buffered crosslinker solution, or both solutions. The two solutions are combined to initiate the crosslinking reaction and form the hydrogel as described for prior embodiments. The wetting agent serves to promote curing and adhesion of an in-situ composition of the hydrogel onto an oily target surface such as the skin, liver or gall bladder.

[0080] In a tenth embodiment, a flexibilizer such as collagen may be added to either the neutral to basic solution of polysaccharide and synthetic polymer, the buffered crosslinker solution, or both solutions. The two solutions are combined to initiate the crosslinking reaction and form the hydrogel as described for prior embodiments. The type and quantity of flexibilizer incorporated into the hydrogel composition can be adjusted to vary the ductility and elasticity of the cured hydrogel.
In an eleventh embodiment, specific salts and/or buffers can be used as solvents for dissolving the polysaccharide, synthetic polymer, and crosslinker. For example, the polysaccharide and synthetic polymer may be dissolved in a sodium borate buffer adjusted to a neutral or basic pH. The crosslinker may be dissolved in a sodium phosphate buffer adjusted to a neutral or acidic pH. The combination of the two solutions will result in a buffered solution containing the three components of the hydrogel at a pH that results in a crosslinking reaction rate that is appropriate for a given application (e.g., gelation in less than 10 seconds for a spray application, gelation in less than 10 minutes for a casting application, etc.). Specific salts and buffers may be chosen to accommodate additional components that may comprise the composition of the invention. For example, monosodium phosphate salt may be used to achieve an acidic buffer suitable for dissolving both the crosslinker and a steroid.

In a twelfth embodiment, a filler such as hydroxyapatite, fibrous silk, carbon fiber, bone chips, a mesh of polyglycolic acid, a mesh of TephaFLEX® and the like may be added to either the neutral to basic solution of polysaccharide and synthetic polymer, the buffered crosslinker solution, or both solutions. The two solutions are combined to initiate the crosslinking reaction and form the hydrogel as described for prior embodiments. The filler serves to alter the mechanical characteristics of the hydrogel, including but not limited to strength, toughness, tear resistance, compressive modulus, and tensile modulus. Alternatively, the polysaccharide and synthetic polymer are dissolved in a neutral or basic buffer. The crosslinker is dissolved in an appropriately pH balanced buffer. The two solutions are combined and poured or sprayed into a mold containing the filler material to allow the formation of a hydrogel network between the polysaccharide, the synthetic polymer, and the crosslinker around and/or within the filler.

In a thirteenth embodiment, a stabilizer such as trimethylidihydroquinone may be added to either the neutral to basic solution of polysaccharide and synthetic polymer, or a powder form of the crosslinker component. The inclusion of a stabilizer serves to extend the shelf life of the components prior to mixing in the in-situ crosslinking configurations of the invention. At the point of use, the powder form of the crosslinker is dissolved in an appropriately pH balanced buffer solution and combined with the polysaccharide/synthetic polymer solution to initiate the crosslinking reaction and form the hydrogel as described for prior embodiments.

In a fourteenth embodiment, a foaming agent such as sodium bicarbonate may be added to either the neutral to basic solution of polysaccharide and synthetic polymer, the buffered crosslinker solution, or both solutions. The two solutions are combined to
initiate the crosslinking reaction and form the hydrogel as described for prior embodiments. The presence of the sodium bicarbonate induces the formation of bubbles and the foaming of the mixture of reacting solutions, resulting in a hydrogel that exhibits a macroporous structure. Alternatively, the foaming agent can be added to a mixture of the polysaccharide/synthetic polymer and crosslinker solutions after the two solutions have been mixed (while the crosslinking reaction is progressing). In another method, the foaming agent can be placed in a mold or cast that receives the combined polysaccharide/synthetic polymer and crosslinker solutions. The average pore size, distribution of pore sizes, total pore volume and other characteristics of the foamed hydrogel can be controlled by adjusting the amount of foaming agent incorporated into the composition of the invention.

[0085] In a fifteenth embodiment, an absorbent sponge is fabricated by freeze drying the product of the combination of a neutral to basic buffer comprising the polysaccharide and synthetic polymer and an appropriately pH balanced buffer comprising the crosslinker. The sponge may be swelled in a solution comprising a biologically or pharmaceutically active agent, and then coated with an in-situ crosslinking formulation of the composition of the invention. The release of the biologically or pharmaceutically active agent would be dependent on the size of the agent relative to the mesh size of the in-situ cured coating. If the size of the agent is significantly higher than the mesh size of the coating, the agent would be retained until the coating has substantially degraded or worn away. If the size of the agent is approximately similar to the mesh size of the coating, the agent would diffuse out of the sponge at a rate dictated in part but not limited to the diffusion gradient across the coating, the tortuosity of the average path through the coating, the charge of the agent relative to the coating, the thickness of the coating, and the degree of hydration of the coating, among other parameters. The coating may be applied using a spraying and/or dip coating method, as an overmolded casting technique, or other methods known in the art. The coating may integrate into the surface of the sponge through covalent bonding, mechanical interlocking, or charge differences among others. Alternatively, the coating may not integrate with the sponge and serve as free-floating shell or frictionally bound shell around a core the sponge material. The coating may be applied to the core sponge when the sponge is in the hydrated, semi-hydrated, or dried states. For example, the core sponge may be coated in the dry state, and the coated sponge may be immersed in a loading solution of biologically or pharmaceutically active agent. Alternatively, the core sponge may be immersed in a loading solution of biologically or pharmaceutically active agent, allowed
to dry, then coated in the dry state. In another example, the core sponge may be immersed in an appropriate solution to a desired level of hydration and coated, with the resultant hydrated core, coated material immersed in a second solution containing a biologically or pharmaceutically active agent. Any of the above examples may be implanted in the dry, semi-hydrated, or hydrated states after loading of the coated sponge is substantially complete.

In another example, a biologically or pharmaceutically active agent may be incorporated into the polysaccharide and synthetic polymer solution and/or the crosslinker solution during the fabrication of the core sponge material. The incorporation may comprise but is not limited to covalent bonding, electrostatic and/or van Der Walls interactions, hydrophobic interactions, and entrapment among others. The loaded sponge material may then be coated with an in-situ crosslinked coating as described above. The in-situ crosslinked coating may comprise at least one additional, different, biologically or pharmaceutically active agent to enable the delivery of at least two different agents from a single material. The release rates of the agents would be dictated by their respective diffusion constants through the core sponge and/or the coating and the degradation rates of the core sponge and/or coating. In another example, the same biologically or pharmaceutically active agent may be loaded into the sponge and the core to achieve an extended or modulated release profile. The release profile can be modified by altering the degradation times of the sponge and coatings, the density of the hydrogel network of the sponge and coatings, the relative size of the sponge and the thickness of the coatings among others. In yet another example, one agent may be incorporated into the sponge during the fabrication of the sponge, a second agent may be loaded into the sponge through a swelling method as previously described, and a third may be incorporated into the coating. Additionally, layering successive coats of in-situ curing polymer can be performed to modify the structural, mechanical, and release profiles of the materials. Each layer may have unique properties including but not limited to degradation times, method of degradation, crosslink density, percentage of polymeric material, equilibrium swelling, ductility, compressive modulus, hydrophilicity, and the like. It should be obvious to one of skill in the art that permutations of the structural and mechanical characteristics of the coating and sponge, the order of loading of the materials with active agents, and the type of active agents beyond those listed here are achievable.

In a sixteenth embodiment, the polysaccharide and synthetic polymer are dissolved in a neutral or basic buffer. The crosslinker is dissolved in an appropriately pH
balanced buffer. The two solutions are combined to allow the formation of a hydrogel network between the polysaccharide, the synthetic polymer, and the crosslinker with a gelation time on the order of tens of minutes. The combined solutions are transferred into a mold wherein the volume of the solution is less than the volume of the mold. The mold is then rotated (e.g. using a lathe, centrifuge, or similar apparatus) to coat the internal walls of the mold with the combined solution. The rotation of the mold is halted after gelation is complete, and the hollow, cured hydrogel is removed from the mold. The cavity in the center of the hydrogel can be used as a reservoir for a biologically or pharmaceutically active agent, a saline solution, or the like. The cavity may be filled with a desired solution prior to or after implantation of the hydrogel into the target anatomy. The cavity may be refilled with the desired solution via a syringe, catheter, filling tube, or other mechanism if the solution elutes out of the material prior to the conclusion of a course of treatment.

**Utility**

[0088] The compositions described herein may combine multiple utilities as described below. For example, the hydrogel may be applied or deposited to prevent leakage across suture lines or anastomoses following therapeutic or interventional procedures, including coronary artery bypass grafting, carotid endarterectomy, synthetic graft procedures as described in U.S. Pat No. 7,303,757, biopsy as described in U.S. Pat Nos. 6,350,244, 6,592,608, 6,790,185, 6,994,712, 7,001,410, 7,329,414, and 7,766,891, liver or kidney transplantation as described in U.S. Pat. No. 7,226,615, hernia repair, gastric bypass, lung resection, lung volume reduction, bone void filling, cartilage repair as described in U.S. Pat. Nos. 5,716,413, 5,863,297, 5,977,204, 6,001,352, 6,156,068, 6,203,573, 6,511,511, 6,514,286, and 6,783,712, and topical incisions as described in U.S. Pat. Nos. 7,371,403, 7,482,503, and 7,776,022 (acting as a hydrogel bandage), wounds, or ulcers. All recited patents listed in the preceding paragraph are herein incorporated by reference in their entirety.

[0089] In ophthalmology, the sealant may be used to seal clear corneal incisions to provide a soft lubricious surface barrier to protect the ocular surface incisions from the external environment, such as described in U.S. Published Pat. App. Nos. 2007/0196454 and 2009/0252781. In neurosurgery and/or orthopedic surgery, the sealant may be used to repair dural tears or incisions to ensure a water tight seal preventing CSF leakage as
taught in U.S. Pat. No. 6,566,406. All recited patents listed in the preceding paragraph are herein incorporated by reference in their entirety.

The composition may be used as an embolic for aneurysmal closure. The form of the invention may include but is not limited to the following: a liquid composition that crosslinks to form a solid material in the aneurysm, a dry composition that swells when exposed to liquid within the aneurysm, and a dry coating placed over a traditional coil to improve the efficacy and space filling characteristics of the coil. The composition may be used for the occlusion of neurovascular and/or peripheral aneurysm or the occlusion of Fallopian tubes and/or seminal vesicles for sterilization. Additional applications of the composition on the invention are in varicose vein embolization, uterine fibroid embolization, embolization of hypervascularized tumors, embolization of arterio-venous malformations, meningioma embolization, paraganglioma tumor embolization, and metastatic tumor embolization as taught in U.S. Pat. 7,670,592 and herein incorporated herein by reference in its entirety. The treatment of tumors may or may not include chemotherapeutic agents as a component of the hydrogel.

The composition may be used as a hemostat. One form of the invention is a solid bandage for hemorrhagic control in trauma in civilian and military applications as a first responder survival means as described in U.S. Pat. No. 7,371,403, 7,482,503, and 7,776,022. A further example of the use of the composition of the invention as a hemostat is to close punctures of the femoral radial or brachial arteries post catheter based diagnostic or interventionalal procedures as taught in U.S. Pat. Nos. 7,331,979, 7,335,220, 7,691,127, 6,890,343, 6,896,692, 7,083,635, 4,890,612, 5,282,827, 5,192,302, and 6,323,278. An additional example is the management of traumatized, broken, burned, or lacerated mucosal linings, such as the tonsils post tonsillectomy, adenoids post adenoidectomy, after tooth removal, to treat dental dry socket, to treat epistaxis, or treat disruption of any other mucosal surfaces where bleeding control is required. The composition may be used to provide hemostatic control post removal of tissue for biopsy purposes as experienced in liver, lung, kidney, breast, soft tissue, and lymph node biopsies as taught in U.S. Pat Nos. 5,080,655, 5,741,223, 5,725,498, and 6,071,301. All recited patents listed in the preceding paragraph are herein incorporated herein by reference in their entirety.

The composition may be used to act as an agent for the treatment of diabetic foot ulcers, venous stasis ulcers, pressure ulcers, or ulcers and lacerations of any type that require advanced wound management. The purpose of these materials is to provide a moist environment to cover and protect the exposed tissue, and sometimes to stimulate
optimal healing as taught in U.S. Pat Nos. 4,963,489, 5,266,480, and 5,443,950. All patents listed in the preceding paragraph are herein incorporated herein by reference in their entirety.

[0093] The composition may be used as an adhesion barrier in general, gynecologic, and ENT surgical applications to reduce the incidence, extent, and severity of post-operative adhesions. Adhesions are a type of scar tissue that forms a connection between two organs or surfaces that are normally separate in the body. It is hypothesized that the free blood and plasma that result from surgery can form fibrin strands between tissues acutely; these strands can mature within a time span of days into permanent tissue bands which can interfere with normal organ function and lead to other serious clinical complications. They are sometimes associated with endometriosis and pelvic inflammatory disease and are known to frequently form after abdominal, pelvic, or sinus surgery as taught in U.S. Pat Nos. 5,852,024, 6,551,610, and 5,652,347. Over 90% of patients that undergo surgical procedures of this type may form adhesions. The composition may be formed such that a lumen is maintained in the body of the composition to enable ongoing airflow (i.e. during application following sinus surgery) or drainage of fluids. The composition may also be used as a stent to maintain separation between tissues. For example, the composition may be formed into a cylindrical structure and inserted into a sinus ostium that has been dilated to maintain the dilation of the ostium while the tissue heals. In another example, the composition may be used as an ethmoid spacer to maintain an opening into the ethmoid sinuses following surgery. In yet another example, the composition of the invention may be a cylindrical structure of freeze-dried hydrogel that is immersed in a solution of a biologically or pharmaceutically active agent, coated with an in-situ crosslinkable composition of the invention, and inserted into the frontal or ethmoid cells to provide local delivery of the biologically or pharmaceutically active agent. All patents listed in the preceding paragraph are herein incorporated herein by reference in their entirety.

[0094] The compositions described herein may be used as a surface coating on medical devices or tissues to prevent the formation of biofilm, and bacterial or fungal colonies. The selection of a strongly cationic polysaccharide (e.g., Chitosan) as a component of the hydrogel network allows for a continuous surface coating on implants and disposable medical devices that provides a hindrance to biofilm deposition (Carlson, R.P. et. al., Anti-biofilm properties of chitosan coated surfaces. Journal of Polymer Science, Polymer Edition, 19(8): pp1035-1046, 2008). The mechanism of action may be twofold, the physical structure of the polysaccharide may function disrupt the bacterial cell wall or
the cationic nature of the polysaccharide may be exploited to bind with anionic antibiotic agents. Alternatively, a non-polysaccharide component or additive may be used to provide similar antimicrobial, antibacterial, or antifungal properties (e.g. silver). An important application of a surface coated that provides infection control is in the prevention or treatment of osteomyelitis. Osteomyelitis is an infection of bone or bone marrow with a propensity for progression due to pyrogenic bacteria. The presentation of osteomyelitis can be observed due to iatrogenic causes such as joint replacements, internal fixation of fractures, or root canalled teeth. The hydrogel composition of this invention could allow for localized sustained antibiotic therapy. Furthermore, the composition may be designed to prevent or mitigate bacterial or fungal infections, reducing or eliminating the need for prolonged systemic antibiotic therapy as taught in U.S. Pat Nos. 5,250,020, 5,618,622, 5,609,629, and 5,690,955. All patents listed in the preceding paragraph are herein incorporated herein by reference in their entirety.

[0095] The compositions described herein can be used effectively to form porous and non-porous scaffolds of controlled microstructure favorable to cell seeding and tissue engineering applications. Methods of control of pore size and structure include the following: freeze drying (lyophilization), salt extraction, the use of foaming agents such hydrogen peroxide, and other methods well known in the art. Multiple cell lines are of contemporary interest to enable the growth and repair of complex tissues using these porous and non-porous scaffolds such as vasculature, epithelial tissue, Islet cells for the formation of a tissue engineered pancreas, nerve regeneration, cartilage regeneration and repair, bone growth and repair, and connective and soft tissue repair (ventral and inguinal hernia, pelvic floor reconstruction, vaginal slings, rotator cuffs, tendon, etc.).

[0096] The hydrogel composition of this invention may be used in the controlled delivery or administration of therapeutic or palliative agents. The composition may include a synthetic component that acts as a carrier or depot for the therapeutic or palliative agent. The agent may be covalently bound to the structure of the hydrogel matrix or physically entrapped within the hydrogel matrix. The rate of release of the therapeutic or palliative agents may be controlled by modifying the composition of the invention. In one example, the composition may be formed into a hollow chamber to allow injection of a solution containing therapeutic or palliative agents. The chamber containing the therapeutic or palliative agents is then placed at the target anatomy (e.g. inserted into the ethmoid sinus, the frontal sinus cells, agar nasi cells, maxillary sinus, etc.) and the agent or agents then diffuse through the wall of the chamber over time. Alternatively, the therapeutic or palliative agent may be incorporated into the structure of the composition
via bonding or encapsulation. This allows the release profile of the therapeutic or palliative agents to be modified by either the diffusion rate of the agent or agents through the hydrogel or the degradation rate of the hydrogel, or both mechanisms proceeding concurrently. In another example, the hollow chamber may be inserted into the target anatomy, then filled with a solution containing the therapeutic or palliative agents of interest. Targets of contemporary interest include the following: paclitaxel for the treatment of tumors, insulin for the treatment of diabetes, analgesics or anesthetics for the treatment of pain, vasoconstrictors for the control of blood pressure such as amphetamines, antihistamines, pseudo-ephedrine, and caffeine, vasodilators for the control of blood pressure such as alpha blockers, nitric oxide inducers, and papavarine, cholesterol lowering drugs such as statins (e.g., lovastatin), procoagulants for the control of clotting such as protamine sulfate, thrombin, fibrin, and collagen, anticoagulants for the control of clotting such as heparin, Coumadin, glycoprotein 2-β-3-α, warfarin, abciximab, Ticagrelor, and clopidogrel bisulfate, and selective serotonin reuptake inhibitors such as fluoxetine to provide palliative treatment of depression, obsessive/compulsive disorders, bulimia, anorexia, panic disorders, and premenstrual dysphoric disorders, mono amine oxidase inhibitors such as phenelzine for the palliative treatment of depression, and glucocorticoids for the treatment of inflammation of the nasal sinus cavity associated with chronic rhinosinusitis. The hydrogel compositions may be used as a carrier for synthetic and human-based bone regrowth agents such as recombinant human bone morphogenetic protein as well as biomimetic materials usable for this indication such as B2A, F2A, PBA, LAI, VA5, PBA, LAI, VA5, B7A, F9A, F5A, and F20A from BioSurfaces Engineering Technology, heterodimeric chain synthetic heparin-binding growth factor analogs as taught in U.S. Pat. No. 7,528,105, positive modulator of bone morphogenetic protein-2 as taught in U.S. Pat. Nos. 7,482,427 and 7,414,028, growth factor analogs as taught in U.S. Pat. No. 7,414,028, and synthetic heparin-binding growth factor analogs as taught in U.S. Pat. No. 7,166,574, all of which are incorporated herein by reference in their entirety.

[0097] The compositions of the current invention have a variety of uses especially in the area of cosmetic surgery and dermatology. Malleable, flowable compositions may be prepared as injectable formulations, and are suitable for superficial to deep dermal augmentation, for example to correct, fill, and support dermal wrinkles, creases, and folds as well as lips as taught in U.S. Pat. Nos. 5,827,937, 5,278,201 and 5,278,204. Larger volume injections can be envisioned for augmentation of breast, penile glans, and
other anatomic positions in the body as taught in U.S. Pat. No. 6,418,934; all listed patents are incorporated herein by reference in their entirety.

[0098] Body sculpting procedures, including breast augmentation, are contemplated for cosmetic and reconstructive purposes. Augmentation of the glans of the penis is used for treatment of premature ejaculation. Historically, the main limitation of medical treatment for premature ejaculation is recurrence after withdrawal of medication. Glans penis augmentation using injectable compositions of the invention facilitate treatment of premature ejaculation via blocking accessibility of tactile stimuli to nerve receptors. The compositions of the invention could also be used as an injectable bulking agent for sphincter augmentation to control incontinence. In this application, the material is injected directly into the sphincter tissue to improve and augment the tissue structure such that sphincter control could be restored.

[0099] The composition described herein may be used as a space filling agent and energy barrier to attenuate existing energy-based procedures and reduce current dose limiting morbidity issues in adjacent tissue. The hydrogel composition of this invention acts as a transient buffer between the non-diseased tissue and the tumor target. The benefits of this approach are twofold; the space filling attribute of the formulation physically moves the collateral tissue away from the target tumor towards which the energy is applied, furthermore, the composition may be formulated to include additives that attenuate the strength of the applied radiation or other energy. For example, the composition may be used to mitigate or reduce radiation damage of the prostate during radiotherapeutic procedures. The displacement of the tumor away from healthy tissue described herein is also applicable to head and neck cancer, pelvic, thoracic, breast and soft tissue sarcomas. A further use of this composition in radiotherapy and surgical tumor removal procedures is using the composition as a marking system to delineate the boundary of the tumor.

[00100] The compositions of the current invention may be used to fill voids in tissue. Potential uses include the treatment of voids in bone, both weight bearing and non-weight bearing, the treatment of voids or gaps in articular cartilage, voids caused by a biopsy procedure, and septal defects of the heart. The treatment of these voids can be enhanced by the inclusion of biologically active agents and biologically activating agents in the hydrogel formulation. For example, recombinant human bone morphogenic protein or allograft human derived bone materials, or demineralized bone matrices, or synthetic biomimetic growth factor materials may be incorporated into the composition to aid in the treatment of bone voids.
The compositions described herein may be used to adhere two or more tissues to each other, or to adhere an implant or disposable medical device to a tissue. For example, a cured, partially hydrated variant of the formulation may be used to adhere a hearing aid to the ear drum. The ability of the semi-hydrated hydrogel to conduct pressure waves will allow the conduction of sound from the hearing aid to the middle ear. Further applications of the adhesive variants of the composition may include mucosal or buccal bandages or coverings for laceration of the dermis.

The compositions of the current environment can be may be used as a synthetic synovial fluid or other type of lubricating agent. By incorporating synthetic polymers that are highly hydrophilic, these materials may find application in fields such as tendon or ligament repair and thoracic surgery. The adhesion of a lacerated tendon that has undergone surgical repair to the tendon sheath reduces the range of motion of the affected digit or limb and increases the work required to attain the range of motion that remains. The deposition of a flowable slurry of the hydrogel composition between the surgically repaired tendon and the tendon sheath may act to reduce friction and enable a lower work of extension for the affected tendon. In another application, a thin layer of the composition may be sprayed onto or otherwise applied to a tendon to form a lubricious coating that prevents adhesion between the tendon and the tendon sheath. In thoracic surgery, adhesions may form after thoracic interventions. The introduction of a hydrogel described herein may prevent or reduce the formation of adhesions between the pleura, and in addition, provides a lubricant to movement of the adjacent tissue past each other.

The compositions described in the invention may be applied as a spray coating. The multiple components of the formulation may be applied sequentially or concurrently to enable curing via partial or full crosslinking at the target site. Spray coatings may be applied to a variety of medical devices and implants, including implantable orthopedic devices, coronary, peripheral, neurovascular stents, catheters, cannulas, and the like. Additionally, the spray coating may be applied to issues as a sealant or adhesion barrier, to wounds or lesions to aid in or accelerate healing or to act as a sealant, as a protective coating for the eye, or for drug delivery. As a detailed example, an orthopedic implant may be spray coated with formulations designed to promote osteogenesis and or osteoinduction and or osteoconduction, to prevent the formation of bacterial, microbial, or fungal colonies, to assist in the load bearing characteristics of the implant, or to act as a depot for the delivery of biologically active or biologically activating agents.
The compositions described in the invention may be applied as a liquid for in-situ curing via partial or complete crosslinking. The multiple components of the formulation may be applied sequentially or concurrently to enable curing or crosslinking at the target site. These embodiments may be applied by injecting the formulation into the core or recesses of implants to be placed in the body to provide local drug delivery including but not limited to analgesics, antibiotics, procoagulants, chemotherapeutic agents, and anticoagulants, or tissue engineering features including but not limited to osteogenesis, osteoinduction, and osteoconduction. Implants intended for placement in the body may also be dip coated in the liquid formulations described herein. These coatings may be allowed to dry for long term storage; they may be implanted in the dry or rehydrated state. In the dry form, it is anticipated that the material could be rehydrated in situ. The liquid formulations may be introduced into a tissue void including but not limited to bone voids, post biopsy orifices, and septal heart defects. The liquid formulations may be introduced to augment the shape or form of existing structures including but not limited to breast, lips, and naso-labial folds. The liquid formulations may also be used as an embolic for the treatment of but not limited to neurovascular and peripheral vascular aneurysms, uterine fibroids, metastatic and benign tumors, and varicose veins. The liquid formulation may be used to provide protection, lubrication, and cushioning to the eye following surgery. The liquid formulation may be used as a method for the delivery or application of drug, biologic, and biomimetic materials. The liquid formulation is also useful as sealant for the treatment of but not limited to access to the dura mater, access to the spine, or access to the vasculature.

The compositions described in this invention may be applied as a cured or substantially fully crosslinked material that may or may not be hydrated. Fields of use for this embodiment of the invention may include but are not limited to the following: wound healing as a preformed covering with or without an adhesive backing (as commonly used in bandage form), as a solid embolic for the treatment of neurovascular or peripheral aneurysms, uterine fibroids, metastatic and benign tumors, or varicose veins, as an adhesive to connect two or more tissues or materials, as an adhesive to attach implants such as a hearing aid to tissues, and as a method of drug delivery. The non-hydrated, cured (substantially fully crosslinked), materials may be subsequently processed (e.g. necking, stretching, forming, cutting, etc.) to attain other desirable characteristics. These processed materials may be used in the applications noted in the specification herein. For example, the hydrogel may be cast as a tube, and necked to a reduced diameter or profile that facilitates insertion into a tight lumen or limited space.
which is generally desirable in the art for minimally invasive and percutaneous catheter
based medical technologies. One specific example in which this embodiment would be
useful is to control trauma wherein the cast hydrogel that has been necked would be
inserted into narrow tissue wound formed by the passage of a bullet through said tissue.
The material could be inserted by an emergency room technician in a civilian setting or a
medic in a military setting as a fast acting tourniquet that facilitates movement of the
patient to a more stable medical treatment environment. It is also contemplated as
another example the treatment of neurovascular aneurysms wherein the non-hydrated,
cured material would be necked to facilitate passage and delivery through the lumen of
microcatheters commonly used in interventional neuroradiology procedures. The cured,
necked hydrogel could then be deposited into the aneurysm similar to contemporary
metalic detachable coils to facilitate closure or exclusion of the aneurysm.

[00106] The cured (fully or partially crosslinked) compositions described in this invention
may be formulated as a powder. The powder is processed by being ground, milled,
chopped, cryomilled, fragmented through syringe to syringe mixing, or any other process
that may be used to reduce the size of a material to a desired particle size. The processes
may be undertaken while the material is in the hydrated, partially hydrated, or non-
hydrated forms. Alternatively, spray drying may be used to obtain a fine powder of the
composition by employing hot gas to force a slurry of the composition out of an atomizer
or spray nozzle. The slurry may contain the components of the composition in an
unreacted, partially reacted, or fully reacted state. In some cases, the individual elements
of the composition may be introduced to the atomizer or spray nozzle through separate
feed lines to prevent the initiation of the crosslinking reaction prior to passage through
the atomizer or spray nozzle. The partially crosslinked embodiment is particularly suited
towards subsequent in situ or topical reactions where the reaction enables but is not
limited to the following: acting as a sealant, acting as an embolic agent, acting as a
hemostat, acting as a surface coating, acting as a lubricant, acting as an adhesive, acting
as a void filler, acting as a space filling agent, or any of the other applications covered in
this specification. This embodiment may have application as a topical dressing with
hemostatic properties.

[00107] The compositions described in this invention may be formulated as a rehydrated
powder. The rehydrated powder may consist of the cured (partially or fully crosslinked)
hydrogel material that has been ground, milled, chopped, cryomilled, fragmented
through syringe to syringe mixing, or any other process that may be used to reduce the
size of a material to a desired particle size and subsequently rehydrated. This
embodiment may have application in the following exemplary areas: the treatment of diabetic ulcers, the treatment of sinus and mucosal lesions, as an embolic agent, as a protective coating for tendon, ligament, or the pleural interface, as a method for drug delivery, as a method for tissue augmentation (dermal fillers, vocal fold filler, etc.), as a filler for breast implants, and as a filler for resorbable implants such as those used for placement against bone and for filling of voids such as between bones as taught in US. Published Pat. App. 2006/0241777 and herein incorporated by reference in their entirety.

**Kits**

[00108] Also provided are kits for use in practicing the subject methods, where the kits typically include the distinct substrate and crosslinker components of the composition, as described above. The substrate and crosslinker components may be present in separate containers in the kit, e.g., where the substrate is present in a first container and the crosslinker is present in a second container, where the containers may or may not be present in a combined configuration. The requisite buffer solutions for the substrate and crosslinker compositions may be provided in additional, separate, containers. Containers are understood to refer to any structure that may hold or surround the components of the hydrogel composition of the invention; exemplary containers include syringes, vials, pouches, capsules, ampules, carpules, cartridges, and the like. The containers may be shielded from visible, ultraviolet, or infrared radiation through the use of additional components (e.g. a foil pouch surrounding a syringe) or through selection of the material properties of the container itself (e.g. an amber glass vial or opaque syringe).

[00109] The subject kits may also include a mixing device, for mixing the substrates and crosslinking composition together to produce the composition of the invention. The kits may also include a delivery device (which may or may not include a mixing element), such as a catheter devices (e.g. tubes with one or more lumens of identical or differing sizes and shapes with exit points of varying geometries, dimensions, and positions), syringe(s) of similar or different diameters and volumes, spray elements, check valves, stopcocks, Y-connectors, air bleeder elements (e.g. a membrane that permits the removal of air from a liquid solution prior to delivery to the patient), inlet ports or chambers for the introduction of a forced air stream, disposable cartridges that allow for prolonged deposition of the hydrogel composition, applicators or spreaders, assemblies for realizing a mechanical advantage in delivering the composition of the invention, housings or casings to protect and contain the above mentioned components, and the like.
The kit may further include other components, e.g., desiccants or other means of maintaining control over water content in the kit, oxygen scrubbers or other means of maintaining control over oxygen content within the kit, an inert gas atmosphere (e.g. nitrogen or argon), indicators to convey the maximum temperature experienced by the kit, indicators to convey exposure to sterilizing radiation, ethylene oxide, autoclave conditions, and the like, retaining or positioning structures to prevent damage to the components (e.g. trays or packaging card), that are required to maintain the product in good condition during transport and storage.

Examples of a kit for the deployment and in situ formation of the hydrogel composition of the invention include, but are not limited to:

Two sealed vials, one containing the nucleophilic component(s) and the other containing the electrophilic component(s), two syringes, one containing the buffer for the nucleophilic component(s) and the other containing the buffer for the electrophilic component(s), a casing for containing and stabilizing the syringes, a casing for housing and stabilizing the vials, and a connecter element within the vial housing that holds needles positioned to pierce the septa on the vials when the syringe casing and vial casing are mated together. The user fills the syringes by mating the two casings (driving the needles through the respective septa), injecting the buffer solutions into the vials, and withdrawing the reconstituted solutions into the syringes. The user may then attach a delivery device to the syringes as needed (see exemplary delivery device elements above for a non-inclusive list).

A second kit for in situ delivery and formation of the hydrogel formulation may consist of two dual chamber mixing syringes (e.g. Vetter Lyo-Ject®); one syringe contains the nucleophilic powder and the nucleophilic buffer, the other contains the electrophilic powder and electrophilic buffer, and a syringe casing that houses the two dual chamber syringes. The user depresses the syringe plungers to transfer the buffers from the proximal chambers into the distal powder chambers and reconstitute the powders. The user may then attach a delivery device to the syringes as needed (see exemplary delivery device elements above for a non-inclusive list).

A third kit for in situ delivery and formation of the hydrogel formulation may consist of a syringe containing the nucleophilic substrate reconstituted with an appropriate buffer, a sealed vial containing the electrophilic substrate powder, a second syringe containing the electrophilic buffer, a casing for containing and stabilizing the syringes, a casing for housing and stabilizing the single vial, and a connecter element within the vial housing that holds a needle positioned to pierce the septum on the vial
when the syringe casing and vial casing are mated together. The user fills the syringes by mating the two casings (driving the needle through the septum), injecting the electrophilic buffer solution into the vial, and withdrawing the reconstituted solution into the syringe. The user may then attach a delivery device to the syringes as needed (see exemplary delivery device elements above for a non-inclusive list).

[00115] A fourth kit for in situ delivery and formation of the hydrogel formulation may consist of a syringe containing the nucleophilic substrate reconstituted with an appropriate buffer and a sealed chamber containing the freeze dried electrophilic powder separated by a one way check valve. Depressing the syringe introduces the nucleophile solution into the electrophile powder chamber, rapidly reconstituting the electrophile and beginning the crosslinking reaction. Continued depression of the syringe pushes the activated solution out of the powder chamber and into the accessory components (e.g. a mixing element, cannula or spray tip, etc. as listed above).

[00116] A fifth kit for in situ delivery and formation of the hydrogel formulation may consist of two syringes, one containing the nucleophilic substrate reconstituted with an appropriate buffer and the other containing the electrophilic substrate reconstituted with an appropriate buffer, and a syringe casing. The user may then attach a delivery device to the syringes as needed (see exemplary delivery device elements above for a non-inclusive list).

[00117] A sixth kit for the in situ delivery and formation of the hydrogel formulation may consist of a sponge or swab containing a dry form of the polysaccharide substrate, physiologically acceptable polymer substrate, crosslinking composition, and appropriate buffer salts. The user can deposit a layer of the cured hydrogel formulation by wetting the swab with saline and wiping the wet swab across the target tissue or area. The saline reconstitutes the four components within the swab and begins the crosslinking reaction; this reaction completes after the activated components have been deposited at the target, resulting in the formation of the crosslinked hydrogel formulation. Alternatively, the reaction may be driven by contacting the swab containing the four components with a moist tissue surface such as the cornea of the eye.

[00118] Other kits may be envisioned for the use of a hydrogel formulation that has been cured prior to shipment to the user. The following examples are non-limiting and are meant to demonstrate the potential for kitting the hydrogel formulation.

[00119] In one embodiment, a container provides the cured, dried, and fragmented hydrogel formulation. A syringe is supplied containing a buffer appropriate for rehydrating the powder. The syringe is connected to the fragmented hydrogel container
and the buffer is introduced to the container to rehydrate the fragmented hydrogel. The rehydrated hydrogel formulation is withdrawn into the syringe, at which point the user can connect it to any of the exemplary device elements previously listed.

[00120] In a second embodiment, both the cured, dried, and fragmented hydrogel formulation and the appropriate buffer solution are provided in a dual chamber syringe. The user rehydrates the dry hydrogel fragments by depressing the syringe plunger and combining the buffer solution with the dry hydrogel fragments. The user can then connect the syringe to any of the exemplary device elements previously listed.

[00121] In a third embodiment, the cured, dried and fragmented hydrogel formulation is provided in a syringe in the rehydrated state. The user can connect the syringe to any of the exemplary device elements that have been previously listed.

[00122] In fourth embodiment, the cured, dried and fragmented hydrogel formulation is provided in a pouch or container for direct application to the target site.

[00123] In a fifth embodiment, the cured hydrogel may be dried and provided in any form or geometry. For example, the cured hydrogel may be provided as a thin cylinder for insertion through a catheter; the same form of hydrogel may be provided loaded into a catheter or into a cartridge intended for insertion into a neurovascular catheter. Alternatively, the cured hydrogel may be provided as a spiral or conical spiral for insertion into the nasal cavity to prevent nasal valve collapse and maintain airway patency. In another example, the cured hydrogel may be provided as a woven stent for prevention of tracheal or nasal passage collapse, or for the prevention of adhesion formation between the inner surfaces of a body lumen as taught in U.S. Pat. No. 6,322,590, incorporated herein by reference in its entirety. In yet another example, the cured hydrogel may be provided as a sheet for use as a bandage or dressing. As yet another example, a freeze dried hydrogel formulation may be attached to an adhesive film for use as a bandage or dressing. In an additional example, the hydrogel may be coated on a coiled wire and dried for insertion into a neurovascular aneurysm. When exposed to blood within the aneurysm, the hydrogel coating swells and takes up a much larger space than the coil itself or the combination of the coil and dry hydrogel.

[00124] In a sixth embodiment, the cured hydrogel may be dried and rehydrated and provided in any form or geometry. For example, the rehydrated hydrogel may be provided in a sheet for use as a moist wound covering. In another example, the rehydrated hydrogel may be attached to an adhesive film as a dressing or moist wound covering.
In a seventh embodiment, the cured hydrogel may be provided in a kit with a saline rinse that is pH balanced to accelerate the degradation of the hydrogel. For example, a freeze-dried hydrogel may be provided as a sheet for use in adhesion prevention in which the application of the saline rinse results in a faster degradation of the sheet with respect to the degradation rate of the freeze-dried hydrogel absent the rinse.

In addition to above-mentioned components, the subject kits typically further include instructions for using the components of the kit to practice the subject methods. The instructions for practicing the subject methods are generally recorded on a suitable recording medium. For example, the instructions may be printed on a substrate, such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or subpackaging) etc. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, etc. In yet other embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.

EXAMPLES

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.

EXAMPLE 1

A multi-armed polyethylene glycol with amine active groups was combined with chitosan at a 10:1 ratio of polyethylene glycol to chitosan in sodium borate buffer. An
equal volume of a multi-armed polyethylene glycol with ester active groups reconstituted in sodium borate buffer at a 2:1 ratio of polyethylene glycol ester to polyethylene glycol amine was mixed with the chitosan solution. After one hour had passed, a firm, clear hydrogel had formed (FIG. 4).

EXAMPLE 2

[00129] Three samples were sectioned from a hydrogel fabricated as described in Example 1, weighed, and placed in phosphate buffered saline at 37°C. After twenty four hours had passed, the samples were weighed and the amount of swelling over that time period was calculated as: \(100\frac{(m_{24}-m_{0})}{m_{0}}\) where \(m_{0}\) is the mass of the sample at time zero and \(m_{24}\) is the mass of the sample at twenty four hours. The hydrogels had swelled an average of 143% during over a period of twenty four hours.

EXAMPLE 3

[00130] A multi-armed polyethylene glycol with amine active groups was combined with chitosan at a 10:1 ratio of polyethylene glycol to chitosan in sodium borate buffer. An equal volume of sodium phosphate buffer containing 4% glutaraldehyde (GA) was combined with the chitosan solution. After one hour had passed, a firm, yellow-brown gel had formed (FIG. 5).

EXAMPLE 4

[00131] A multi-armed polyethylene glycol with amine active groups was combined with carboxymethylcellulose (CMC) at a 4:1 ratio of polyethylene glycol to carboxymethylcellulose in sodium borate buffer. An equal volume of a multi-armed polyethylene glycol with ester active groups reconstituted in sodium borate buffer at a 1:1 ratio of polyethylene glycol ester to polyethylene glycol amine was mixed with the carboxymethylcellulose solution. After one hour had passed, a soft, clear hydrogel had formed (FIG. 6).

EXAMPLE 5

[00132] A multi-armed polyethylene glycol with amine active groups was combined with chitosan at a 5:1 ratio of polyethylene glycol to chitosan in sodium borate buffer. An equal volume of a multi-armed polyethylene glycol with ester active groups reconstituted in sodium borate buffer at a 2:1 ratio of polyethylene glycol ester to polyethylene glycol amine was mixed with the chitosan solution. After one hour had passed, a firm, clear
hydrogel had formed. The hydrogel was dried to a constant mass and ground into particulate with a cryogrinding process. An image of the cryomilled particulate is shown in FIG. 7.

EXAMPLE 6

[00133] A multi-armed polyethylene glycol with amine active groups was combined with chitosan at a 5:1 ratio of polyethylene glycol to chitosan in sodium borate buffer. An equal volume of a multi-armed polyethylene glycol with ester active groups reconstituted in sodium borate buffer at a 2:1 ratio of polyethylene glycol ester to polyethylene glycol amine was mixed with the chitosan solution, and the combined solutions were cast into a tray to a depth of approximately 3 mm. The sample was subjected to freeze-drying, after which a 1 cm by 1 cm sample was cut from the larger sample. The material had the consistency of a sponge or dense gauze; it could be manipulated with operations like rolling, pressing, and folding without noticeable damage or tearing. FIG. 8 shows the sample material rolled on itself and held in a pair of forceps.

EXAMPLE 7

[00134] A multi-armed polyethylene glycol with amine active groups was combined with chitosan at a 15:1 ratio of polyethylene glycol to chitosan in sodium borate buffer. An equal volume of a multi-armed polyethylene glycol with ester active groups reconstituted in sodium borate buffer at a 2:1 ratio of polyethylene glycol ester to polyethylene glycol amine was mixed with the chitosan solution, and the combined solutions were cast into a cylindrical mold 0.25" in diameter. The composition was allowed to cure, then it was removed from the mold and air dried to a constant mass and outer diameter of 0.114". The diameter of the rod was further reduced to 0.033" from its cast dimension via a necking process. A sample of the necked rod was cut to a length of 0.5" and placed in water; the mass, length, and diameter of the sample was tracked over time. At approximately 24 hours of exposure to water, the sample had exhibited a 1285% increase in mass, a 44% decrease in length, and a 481% increase in diameter. FIG. 9 shows a sample of the material in the dry and hydrated states.

EXAMPLE 8

[00135] A multi-armed polyethylene glycol with amine active groups was combined with chitosan at a 5:1 ratio of polyethylene glycol to chitosan in sodium borate buffer with methylene blue as a colorant. This solution was loaded into a 1 milliliter syringe. An
equal volume of a multi-armed polyethylene glycol with ester active groups reconstituted in sodium phosphate buffer at a 2:1 ratio of polyethylene glycol ester to polyethylene glycol amine was loaded into a second 1 mm syringe. The syringes were joined to a syringe handle, overmolded connector, mixing element, and spray tip. The delivery system was used to apply a thin, conformable coating of the hydrogel composition to a human hand that cured within seconds of application. The coating was able to adhere to the skin when held in a vertical orientation and could withstand flexure of the palm without rupture or cracking (FIG. 10).

EXAMPLE 9

[00136] A multi-armed polyethylene glycol with amine active groups was combined with chitosan at a 9:1 ratio of polyethylene glycol to chitosan in sodium borate buffer. This solution was loaded into one of the two barrels on a dual syringe applicator. An equal volume of a multi-armed polyethylene glycol with ester active groups was reconstituted in sodium phosphate buffer at a 2:1 ratio of polyethylene glycol ester to polyethylene glycol amine. Methylene blue was added to the sodium phosphate solution for visualization purposes and the solution was loaded into the second barrel of the dual syringe applicator. The dual syringe applicator was combined with plunger caps, a dual syringe plunger, and a spray tip.

[00137] A section of explanted bovine tendon and an intacted section of the tendon sheath was cut to approximately 3 inches in length. The tendon was advanced out of the sheath until approximately 1.5 inches of the tendon was exposed. The delivery system was used to apply a thin (sub-millimeter), conformable coating of the hydrogel composition to the outer surface of the tendon. After four seconds, the tendon was retracted into the sheath using a pair of forceps. The coating was lubricious and non-friable, remaining intact and adherent to the tendon over the course of 20 extension/retraction cycles. FIG. 11 shows a cross sectional image of the bovine tendon with the coating identified by an arrow.

EXAMPLE 10

[00138] A multi-armed polyethylene glycol with amine active groups was combined with chitosan at a 17:1 ratio of polyethylene glycol to chitosan in sodium borate buffer. This solution was loaded into one of the two barrels on a dual syringe applicator. An equal volume of heat treated glutaraldehyde and dextran was reconstituted in sterile water for injection at a heat treated glutaraldehyde:polyethylene glycol ratio of 1:42.5 and a dextran:polyethylene glycol ratio of 1:10 polyethylene glycol. The heat treated
glutaraldehyde/dextran solution was loaded into the second barrel of the dual syringe applicator. The dual syringe applicator was combined with plunger caps, a dual syringe plunger, and a spray tip. The delivery system was used to apply a thin, conformable coating of the hydrogel composition to a human hand. The coating was able to adhere to the skin when held in a vertical orientation and could withstand flexure of the palm without rupture or cracking. FIG. 12 shows a perspective view of the coating as adhered to the skin.

EXAMPLE 11

A multi-armed polyethylene glycol with amine active groups was combined with chitosan at a 9:1 ratio of polyethylene glycol to chitosan in sodium borate buffer. An equal volume of a multi-armed polyethylene glycol with ester active groups reconstituted in sodium borate buffer at a 2:1 ratio of polyethylene glycol ester to polyethylene glycol amine was mixed with the chitosan solution, and the combined solutions were cast into a tray to a depth of approximately 3 mm. The sample was subjected to freeze-drying, after which a 1 cm by 1 cm sample was cut from the larger sample. The sample was placed in a solution of sterile saline to swell for 1 hour.

Concurrently, a kit for the application of a spray coating of the composition was prepared by fabricating a solution of a multi-armed polyethylene glycol with amine active groups was combined with chitosan at a 22:1 ratio of polyethylene glycol to chitosan in an alkaline solution of FD&C Blue No. 1 in sodium borate buffer. This solution was loaded into one of the two barrels on a dual syringe applicator. An equal volume of a multi-armed polyethylene glycol with ester active groups was reconstituted in sodium phosphate buffer at a 2:1 ratio of polyethylene glycol ester to polyethylene glycol amine. The dual syringe applicator was combined with plunger caps, a dual syringe plunger, and a spray tip.

The rehydrated hydrogel was removed from the sterile saline and the dual syringe applicator was used to apply a coating of the in-situ crosslinking form of the composition onto the surface of the hydrogel. FIG. 13. shows a cross section of the coated hydrogel with a ruler as a reference; the scale on the ruler is in millimeters. The coating appeared to adhere and integrate into the surface of the hydrogel, and did not delaminate or fracture when flexed or bent. FIG. 14. shows a cross section of the coated hydrogel held by forceps in a double-over configuration. The coated hydrogel was returned to the sterile saline for 24 hours. At the end of this time, the hydrogel coating had swelled to a
degree notable via visual inspection, however, the coating had not fractured, delaminated, or developed any fissures or irregularities.

EXAMPLE 12

A multi-armed polyethylene glycol with amine active groups was combined with chitosan at a 9:1 ratio of polyethylene glycol to chitosan in sodium borate buffer. An equal volume of a multi-armed polyethylene glycol with ester active groups reconstituted in sodium borate buffer at a 2:1 ratio of polyethylene glycol ester to polyethylene glycol amine was mixed with the chitosan solution, and the combined solutions were cast into a cylindrical mold. The volume of the combined solution was less than that of the mold. The mold was fixed in a lathe and spun to coat the internal walls of the mold with the solution. When the hydrogel had cured, the mold was removed from the lathe and opened to allow the hydrogel to dry and form a hollow, balloon like structure. FIG 15. shows the hydrogel structure at end of the drying period.

The preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims.
That which is claimed is:

1. A hydrogel composition, comprising
   a polysaccharide substrate or derivative thereof having a molecular weight of 160 Dalton
to 80,300 Dalton and comprising at least two reactive nucleophilic groups;
   a synthetic, hydrophilic polymer of a molecular weight of 200 Dalton to 100,000 Dalton
   and comprising at least two nucleophilic reactive groups; and
   a crosslinking agent.

2. The composition of claim 1, wherein the polysaccharide substrate is chitosan,
carboxymethylcellulose, carboxymethylchitosan, or a derivative thereof.

3. The composition of claim 1, wherein the synthetic hydrophilic polymer substrate
   is a polyethylene glycol comprising at least two nucleophilic active groups.

4. The composition of claim 1, wherein the crosslinking agent is a polyethylene
   glycol comprising at least two electrophilic active groups.

5. The composition of claim 1, wherein the crosslinking agent is an aldehyde.

6. The composition of claim 1, wherein the crosslinking agent is a glutaraldehyde or
   a derivative thereof.

7. The composition of claim 1, wherein the crosslinking agent is heat treated
   glutaraldehyde or a derivative thereof.

8. The composition of claim 1, wherein the composition comprises a thickening
   agent.

9. The composition of claim 1, wherein the composition comprises a foaming agent.

10. The composition of claim 1, wherein the composition comprises a biologically
    active agent and or a pharmaceutically active agent.
11. The composition of claim 1, wherein the composition comprises a visualization agent and or radiopaque agent.

12. The composition of claim 1, wherein the polysaccharide substrate is soluble in an alkaline aqueous solution.

13. The composition of claim 1, wherein the polysaccharide substrate is soluble in an aqueous solution with a concentration of at least 30mM.

14. A hydrogel composition, comprising

a chitosan or derivative thereof having a molecular weight of 160 Dalton to 80,300 Dalton with a degree of deacetylation of 30% to 90% and at least two reactive nucleophilic groups, wherein the chitosan or derivative thereof is soluble in an aqueous solution having a basic pH;

a multifunctional, polyethylene glycol polymer of a molecular weight of 200 Dalton to 100000 Dalton and comprising at least two nucleophilic reactive groups, and;

a multifunctional, multi-armed crosslinker of polyethylene glycol having a molecular weight of 200 Dalton to 100000 Dalton and comprising at least two electrophilic reactive groups.

15. The composition of claim 14, wherein the composition comprises a thickening agent.

16. The composition of claim 14, wherein the composition comprises a foaming agent.

17. The composition of claim 14, wherein the composition comprises a biologically active agent and or a pharmaceutically active agent.

18. The composition of claim 14, wherein the composition comprises a visualization agent and or a radiopaque agent.
19. The composition of claim 14, wherein the polysaccharide substrate is soluble in an aqueous solution with a concentration of at least 30mM.

20. A hydrogel composition, comprising

- a chitosan or derivative thereof having a molecular weight of 160 Dalton to 80,300 Dalton with a degree of deacetylation of 30% to 90% and at least two reactive nucleophilic groups, wherein the chitosan or derivative thereof is soluble in an aqueous solution having a basic pH;

- a multifunctional, polyethylene glycol polymer of a molecular weight of 200 Dalton to 100000 Dalton comprising at least two nucleophilic reactive groups, and;

- a multifunctional crosslinker of glutaraldehyde or derivative thereof comprising at least two aldehyde groups.

21. The composition of claim 20, wherein the composition comprises a thickening agent.

22. The composition of claim 20, wherein the composition comprises a foaming agent.

23. The composition of claim 20, wherein the composition comprises a biologically active agent and or a pharmaceutically active agent.

24. The composition of claim 20, wherein the composition comprises a visualization agent and or a radiopaque agent.

25. The composition of claim 20, wherein the polysaccharide substrate is soluble in an aqueous solution with a concentration of at least 30mM.

26. A method of forming the hydrogel compositions of claims 1, 14, or 20, comprising:

- combining in a solution all components of the hydrogel composition, and

- allowing the solution to cure for a sufficient period of time to form the hydrogel composition.
27. The method of claim 26, further comprising;
allowing the hydrogel composition to dry.

28. The method of claim 27, wherein the hydrogel is allowed to dry for a period of
time prior to the completion of the crosslinking reaction.

29. The method of claim 26, further comprising:
fragmenting the hydrogel composition.

30. The method of claim 29, wherein the hydrogel is fragmented after drying.

31. The method of claim 26, further comprising:
casting the hydrogel composition into a predetermined cast shape.

32. The method of claim 31, further comprising:
cutting, folding, stretching, coring, and/or machining the hydrogel composition to a
predetermined shape or dimension that is different from the cast shape.

33. The method of claim 26, further comprising:
incorporating a secondary agent into the hydrogel composition after the hydrogel
composition is formed.

34. A method of reducing leakage across suture lines, anastomoses, or incisions;
comprising:
    depositing the hydrogel composition of claims 1, 14, or 20 over at least a portion of the
    suture line, anastomoses, or incision;
    wherein the positioning of the hydrogel composition reduces leakage of fluid through the
    suture line, anastomoses or incision as compared to the absence of the hydrogel composition.

35. The method of claim 34, wherein the hydrogel composition is formed in situ over
at least a portion of the suture line, anastomoses or incision.

36. The method of claim 35, wherein the components of the hydrogel composition
are deposited concurrently.
37. The method of claim 35, wherein one or more components of the hydrogel composition are initially deposited over at least a portion of the suture line, anastomoses, or incision followed by deposition of the remainder of the composition to form the hydrogel.

38. The method of claim 35, wherein the components of the hydrogel composition are applied as a spray.

39. The method of claim 35, wherein the components of the hydrogel composition are dispensed as a liquid.

40. The method of claim 34, wherein the hydrogel composition is formed prior to deposition.

41. The method of claim 40, wherein the hydrogel composition is dry.

42. The method of claim 40, wherein the hydrogel composition is hydrated.

43. A method of filling or closing vasculature or an aneurysm, comprising: depositing the hydrogel composition of claims 1, 14, or 20 within a targeted vasculature or aneurysm, wherein the depositing of the hydrogel fills or closes the vasculature or aneurysm.

44. The method of claim 43, wherein components of the hydrogel composition are deposited at the targeted vasculature or aneurysm such that the components crosslink at the target vasculature or aneurysm to form the hydrogel composition in situ.

45. The method of claim 43, wherein the hydrogel composition is formed prior to deposition.

46. The method of claim 45, wherein the hydrogel composition is dry.

47. The method of claim 45, wherein the hydrogel composition is hydrated.

48. The method of claim 45, wherein the hydrogel composition is fragmented.
49. The method of claim 43, wherein the hydrogel composition is applied to a surface of a material to form a composite material prior to introduction of the composite material into the targeted vasculature or aneurysm.

50. The method of claim 49, wherein the material is a metal coil and wherein a surface of the metal coil is coated with the hydrogel composition to provide for increased space filling when the coil is deposited into the target vasculature or aneurysm.

51. A method of reducing bleeding of a wound, comprising: positioning the hydrogel composition of claims 1, 14, or 20 over at least a portion of the wound, wherein the positioning of the composition reduces or eliminates the flow of blood from the wound as compared to the absence of the hydrogel composition.

52. The method of claim 51, wherein components of the hydrogel composition are deposited at the wound area such that the components crosslink at the wound to form the hydrogel composition in situ.

53. The method of claim 52, wherein components of the hydrogel composition are deposited at the wound area concurrently.

54. The method of claim 52, wherein one or more components of the hydrogel composition are initially deposited over at least a portion of the wound area followed by deposition of the remainder of the composition at the wound area to form the hydrogel composition.

55. The method of claim 52, wherein components of the hydrogel composition are applied as a spray.

56. The method of claim 52, wherein components of the hydrogel composition are dispensed as a liquid.

57. The method of claim 51, wherein the hydrogel composition is formed prior to being deposited on the wound area.

58. The method of claim 57, wherein the hydrogel composition is dry.
59. The method of claim 57, wherein the hydrogel composition is hydrated.

60. The method of claim 57, wherein the hydrogel composition is fragmented.

61. The method of claim 57, wherein the hydrogel is attached to an adhesive film.

62. A method of managing a wound on a subject that provides for a moist environment that covers and protects exposed tissue, comprising:
   positioning the hydrogel composition of claims 1, 14, or 20 over at least a portion of the wound, wherein the positioning of the hydrogel composition provides a moist environment that at least partially covers and protects the exposed tissue as compared to the absence of the hydrogel composition.

63. The method of claim 62, wherein components of the hydrogel composition are deposited at the wound such that the components crosslink at the wound to form the hydrogel composition in situ.

64. The method of claim 63, wherein components of the hydrogel composition are deposited at the wound concurrently.

65. The method of claim 63, wherein one or more components of the hydrogel composition are initially deposited over at least a portion of wound followed by deposition of the remainder of the composition to form the hydrogel composition.

66. The method of claim 63, wherein components of the hydrogel composition are applied as a spray.

67. The method of claim 63, wherein components of the hydrogel composition are dispensed as a liquid.

68. The method of claim 62, wherein the hydrogel composition is formed prior to deposition.

69. The method of claim 68, wherein the hydrogel composition is dry.
70. The method of claim 68, wherein the hydrogel composition is hydrated.

71. The method of claim 68, wherein the hydrogel composition is fragmented.

72. The method of claim 68, wherein the hydrogel is attached to an adhesive film.

73. A method of applying the hydrogel composition of claims 1, 14, or 20 to a medical implant, comprising:
   depositing the hydrogel composition on a medical implant.

74. The method of claim 73, wherein a surface of the medical implant is coated with the hydrogel composition.

75. The method of claim 73, wherein a recess, void, or lumen of the medical implant in coated of filled with the hydrogel composition.

76. A method of forming a tissue scaffold, comprising:
   forming the hydrogel composition of claims 1, 14, or 20 into a tissue scaffold wherein the tissue scaffold optionally comprises mammalian cells.

77. A method of delivering a therapeutic or palliative agent to a subject, comprising:
   administering to a subject the hydrogel composition of claims 1, 14, or 20 comprising a therapeutic or palliative agent, wherein the administering provides for delivery of the therapeutic or palliative agent to the subject.

78. A method of augmenting existing tissue with a hydrogel composition, comprising:
   administering the hydrogel composition of claims 1, 14, or 20 to a target tissue, wherein the administering provides for the augmentation of existing tissue as compared to the absence of the hydrogel composition.

79. The method of claim 78, wherein components of the hydrogel composition are delivered to the target tissue such that the components crosslink at the target tissue to form the hydrogel composition in situ.
80. The method of claim 78, wherein the hydrogel composition is formed prior to deposition on the target tissue.

81. The method of claim 80, wherein the hydrogel composition is dry.

82. The method of claim 80, wherein the hydrogel composition is hydrated.

83. The method of claim 80, wherein the hydrogel composition is fragmented.

84. A method of forming an energy barrier between a target tissue and an adjacent tissue, comprising:
   positioning the hydrogel composition of claims 1, 14, or 20 at a target area between a target tissue and an adjacent tissue, wherein the positioning of the hydrogel composition reduces transmission of energy from the target tissue to the adjacent tissue as compared to the absence of the hydrogel composition.

85. The method of claim 84, wherein components of the hydrogel composition are delivered to the target area such that the components crosslink at the target area to form the hydrogel composition in situ.

86. The method of claim 85, wherein components of the hydrogel composition are deposited concurrently.

87. The method of claim 85, wherein one or more components of the hydrogel composition are initially deposited at the target tissue followed by deposition of the remainder of the composition to form the hydrogel composition.

88. The method of claim 85, wherein the components of the hydrogel composition are applied as a spray.

89. The method of claim 85, wherein the components of the hydrogel composition are dispensed as a liquid.
90. The method of claim 84, wherein the hydrogel composition is formed prior to deposition.

91. The method of claim 90, wherein the hydrogel composition is dry.

92. The method of claim 90, wherein the hydrogel composition is hydrated.

93. The method of claim 90, wherein the hydrogel composition is fragmented.

94. A method of filling a void in existing tissue, comprising:
positioning the hydrogel composition of claims 1, 14, or 20 in a void in existing tissue
wherein the position of the hydrogel composition at least partially occupies the void in the existing tissue.

95. The method of claim 94, wherein components of the hydrogel composition are delivered to the target area such that the components crosslink at the target area to form the hydrogel composition.

96. The method of claim 95, wherein the components of the hydrogel composition are deposited concurrently.

97. The method of claim 95, wherein one or more components of the hydrogel composition are initially delivered to the target area followed by deposition of the remainder of the composition to form the hydrogel composition.

98. The method of claim 95, wherein the components of the hydrogel composition are applied as a spray.

99. The method of claim 95, wherein the components of the hydrogel composition are dispensed as a liquid.

100. The method of claim 94, wherein the hydrogel composition is formed prior to deposition.

101. The method of claim 100, wherein the hydrogel composition is dry.
102. The method of claim 100, wherein the hydrogel composition is hydrated.

103. The method of claim 100, wherein the hydrogel composition is fragmented.

104. A method of adhering two or more tissues to each other, comprising:
    positioning the hydrogel composition of claims 1, 14, or 20 between at least two tissues
    wherein the positioning of the hydrogel composition provides for adhering the two tissue to each
    other as compared to the absence of the hydrogel composition.

105. The method of claim 104, wherein components of the hydrogel composition are
    delivered to the target tissues such that the components crosslink at the target area to form the
    hydrogel composition.

106. The method of claim 105, wherein the components of the hydrogel composition
    are deposited concurrently.

107. The method of claim 105, wherein one or more components of the hydrogel
    composition are initially delivered to the target tissue or tissues followed by deposition of the
    remainder of the composition to form the hydrogel composition.

108. The method of claim 105, wherein the components of the hydrogel composition
    are applied as a spray.

109. The method of claim 105, wherein the components of the hydrogel composition
    are dispensed as a liquid.

110. The method of claim 104, wherein the hydrogel composition is formed prior to
    deposition.

111. The method of claim 110, wherein the hydrogel composition is dry.

112. The method of claim 110, wherein the hydrogel composition is hydrated.
113. A method of minimizing adhesion or friction between two or more tissues, comprising:
positioning the hydrogel composition of claims 1, 14, or 20 between two or more tissues wherein the positioning of the composition minimizes adhesion or friction between the two or more tissues as compared to the absence of the hydrogel composition.

114. The method of claim 113, wherein components of the hydrogel composition are delivered to the target tissues such that the components crosslink at the target area to form the hydrogel composition.

115. The method of claim 114, wherein the components of the hydrogel composition are deposited concurrently.

116. The method of claim 114, wherein one or more components of the hydrogel composition are initially delivered to the target tissue or tissues followed by deposition of the remainder of the composition to form the hydrogel composition.

117. The method of claim 114, wherein the components of the hydrogel composition are applied as a spray.

118. The method of claim 114, wherein the components of the hydrogel composition are dispensed as a liquid.

119. The method of claim 113, wherein the hydrogel composition is formed prior to deposition.

120. The method of claim 119, wherein the hydrogel composition is dry.

121. The method of claim 119, wherein the hydrogel composition is hydrated.

122. A kit, comprising:
the hydrogel composition of claims 1, 14, or 20, and
a delivery device,
wherein components of the hydrogel composition are provided in solution to form the hydrogel composition to enable delivery of the hydrogel composition to a target area or tissue.
123. The kit of claim 122, wherein components of the hydrogel composition are provided within separate or combined containers, and the kit further comprises buffer solutions within separate or combined containers.

124. The kit of claim 123, wherein components of the hydrogel composition are provided within one or more sealed vials and the buffer solutions are provided within one or more syringes.

125. The kit of claim 124, wherein at least two of the components of the hydrogel composition are provided in a solution in a syringe, the remaining component or components are provided in a sealed vial, and a reconstituting buffer for the remaining component or components is provided in a syringe.

126. The kit of claim 124, wherein the syringes comprise different volumes and/or diameters.

127. The kit of claim 122, wherein at least two of the components of the hydrogel composition are provided within a first chamber of a first dual chamber syringe and a buffer is housed in a second chamber of the first dual chamber syringe;

wherein the remaining component or components are provided within a first chamber of a second dual chamber syringe and a buffer is provided in a second chamber of the second dual chamber syringe.

128. The kit of claim 122, wherein at least two components of the hydrogel composition are provided in solution in a syringe, and the remaining component or components are provided as a powder in a chamber connected to a distal tip of the syringe.

129. The kit of claim 128, wherein the component or components within the chamber are provided in a freeze-dried form.

130. The kit of claim 128, wherein the chamber is connected the distal tip of the syringe via a one-way valve that permits flow from the syringe into the chamber.
131. The kit of claim 128, wherein the chamber comprises features that decrease the dissolution time of the powder in the solution.

132. The kit of claim 122, wherein at least two of the components of the hydrogel composition are provided in a solution in a first syringe, and the remaining component or components are provided in a second syringe.

133. The kit of claim 132, wherein the first syringe and the second syringe comprise different volumes or diameters.

134. The kit of claim 122, wherein the components of the hydrogel composition are provided in a dry form on or within a swab.

135. The kit of claim 122, wherein the delivery device comprises a tube or tubes having one or more lumens of identical or differing sizes and shapes with exit points of varying numbers, geometries, dimensions, and positions.

136. The kit of claim 122, wherein the delivery device comprises one or more syringes of similar or different diameters and volumes.

137. The kit of claim 122, wherein the delivery device comprises a spray element or elements.

138. The kit of claim 122, wherein the delivery device comprises a check valve or valves.

139. The kit of claim 122, wherein the delivery device comprises a stopcock or stopcocks.

140. The kit of claim 122, wherein the delivery device comprises an air bleeder element or elements.

141. The kit of claim 140, wherein the air bleeder element comprises a membrane positioned in line with a flow path of reconstituted components of the hydrogel composition.
142. The kit of claim 122, wherein the delivery device comprises inlet ports or chambers for introduction of a forced air stream.

143. The kit of claim 122, wherein the delivery device comprises a disposable cartridge that provides for prolonged deposition of the hydrogel composition via an exchange of clogged cartridges for fresh cartridges.

144. The kit of claim 122, wherein the delivery device comprises an applicator or spreader.

145. The kit of claim 122, wherein the delivery device comprises assemblies for realizing a mechanical advantage in delivering the composition of the invention.

146. The kit of claim 122, wherein the delivery device comprises housings or casings to protect and contain the above mentioned components.

147. A kit, comprising:
a cured hydrogel composition of claims 1, 14, or 20, and
a delivery device to provide for delivery of the cured hydrogel to a target area or tissue.

148. The kit of claim 147, wherein the cured hydrogel composition is provided in a dry form and/or a fragmented form.

149. The kit of claim 148, wherein the cured hydrogel composition is provided within a first container and a buffer solution is provided within a second container.

150. The kit of claim 149, wherein the first container comprises a syringe, and the second container comprises a second syringe.

151. The kit of claim 149, wherein the first container comprises a pouch, and the second container comprises a syringe.

152. The kit of claim 148, wherein the cured hydrogel composition and a buffer solution are provided within a single syringe.
153. The kit of claim 148, wherein the cured hydrogel composition is a powder in a container.

154. The kit of claim 147, wherein the hydrogel composition is a dry material in any shape or geometry.

155. The kit of claim 154, wherein the geometry of the hydrogel composition is a cylindrical tube.

156. The kit of claim 154, wherein the shape or geometry of the hydrogel composition is a rectilinear sheet.

157. The kit of claim 154, wherein the hydrogel composition is affixed to an adhesive film.

158. The kit of claim 147, wherein the hydrogel composition comprises a water content of between about 0% and about 100% in any shape or geometry.

159. The kit of claim 158, wherein the shape or geometry of the hydrogel composition is a cylindrical tube.

160. The kit of claim 158, wherein the geometry of the hydrogel composition is a rectilinear sheet.

161. The kit of claim 154, wherein the hydrogel composition is affixed to an adhesive film.
FIG. 1
INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 10/55714

A. CLASSIFICATION OF SUBJECT MATTER

IPCP(8) - A61K 9/70; A61K 47/34; A61K 9/14 (2010.01)
USPC - 424/489; 424/422; 424/423; 424/426; 424/490

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPCP(8) - A61K 9/70; A61K 47/34; A61K 9/14 (2010.01)
USPC - 424/489; 424/422; 424/423; 424/426; 424/490

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
IPCP(8) - A61K 9/70; A61K 47/34; A61K 9/14 (2010.01)
USPC - 424/489; 424/422; 424/423; 424/426; 424/490 (keyword delimited)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
PubWEST (PGPB, USPT, EPAB, JPAB), Google
Search terms used: hydrogel, polysaccharide, daltons, molecular weight, reactive nucleophilic groups, nucleophile, synthetic hydrophilic polymer, crosslinking agent

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>US 2007/0031498 A1 (Zong et al.) 08 February 2007 (08.02.2007), para [0002]; [0015]; [0041]; [0042]; [0056]; [0068]; [0070]; [0073]; [0079]; [0080]</td>
<td>1-13</td>
</tr>
<tr>
<td>Y</td>
<td>US 6,602,952 B1 (Bentley et al.) 05 August 2003 (05.08.2003), col 1, in 62 to col 2, in 8; col 3, in 46-52; col 5, in 48-55; col 6, in 53-60</td>
<td>1-13</td>
</tr>
<tr>
<td>Y</td>
<td>US 2006/0025815 A1 (McGurk et al.) 02 February 2006 (02.02.2006), Fig 12A; Fig 12B; para [0033];[0035]; [0070]</td>
<td>5-7, 1</td>
</tr>
<tr>
<td>Y</td>
<td>US 6,703,047 B2 (Sawhney et al.) 09 March 2004 (09.03.2004), col 3, in 66 to col 4, in 16; col 4, in 29-34; col 7, in 28-34</td>
<td>1-13</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

* Special categories of cited documents:
  "A" document defining the general state of the art which is not considered to be of particular relevance
  "E" earlier application or patent but published on or after the international filing date
  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  "O" document referring to an oral disclosure, use, exhibition or other means
  "P" document published prior to the international filing date but later than the priority date claimed
  "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  "&" document member of the same patent family

Date of the actual completion of the international search
14 March 2011 (14.03.2011)

Date of mailing of the international search report
21 MAR 2011

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA-US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-3201

Authorized officer: Lee W. Young
PCT Facs℡: 571-272-4300
PCTOSP: 571-272-7774

Form PCT/ISA/210 (second sheet) (July 2009)
**INTERNATIONAL SEARCH REPORT**

<table>
<thead>
<tr>
<th>Box No. II</th>
<th>Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:</td>
</tr>
<tr>
<td></td>
<td>1. □ Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:</td>
</tr>
<tr>
<td></td>
<td>2. □ Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:</td>
</tr>
<tr>
<td></td>
<td>3. □ Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Box No. III</th>
<th>Observations where unity of invention is lacking (Continuation of item 3 of first sheet)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>This International Searching Authority found multiple inventions in this international application, as follows:</td>
</tr>
<tr>
<td></td>
<td>This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. in order for all inventions to be examined, the appropriate additional examination fees must be paid.</td>
</tr>
<tr>
<td></td>
<td>Group 1 is directed to a hydrogel composition, comprising a polysaccharide substrate or derivative thereof having a molecular weight of 160 Dalton to 80,300 Dalton and comprising at least two reactive nucleophilic groups; a synthetic, hydrophilic polymer of a molecular weight of 200 Dalton to 100,000 Dalton and comprising at least two nucleophilic reactive groups; and a crosslinking agent.</td>
</tr>
<tr>
<td></td>
<td>Please see extra sheet</td>
</tr>
<tr>
<td></td>
<td>1. □ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.</td>
</tr>
<tr>
<td></td>
<td>2. □ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.</td>
</tr>
<tr>
<td></td>
<td>3. □ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:</td>
</tr>
<tr>
<td></td>
<td>4. □ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-13</td>
</tr>
</tbody>
</table>

**Remark on Protest**

□ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

□ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

□ No protest accompanied the payment of additional search fees.

Form PCT/ISA/2.10 (continuation of first sheet (2)) (July 2009)
The claims are deemed to correspond to the Groups listed below in the following manner:

Group I: claims 1-13
Group II: claims 14-25
Group III: claims 26-33
Group IV: claims 34-42
Group V: claims 43-50
Group VI: claims 51-61
Group VII: claims 62-72
Group VIII: claims 73-75
Group IX: claims 76
Group X: claims 77
Group XI: claims 78-83
Group XII: claims 84-93
Group XIII: claims 94-103
Group XIV: claims 104-112
Group XV: claims 113-121
Group XVI: claims 122-161

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I is directed to a hydrogel composition, comprising a polysaccharide substrate or derivative thereof having a molecular weight of 160 Dalton to 80,300 Dalton and comprising at least two reactive nucleophilic groups; a synthetic, hydrophilic polymer of a molecular weight of 200 Dalton to 10000 Dalton and comprising at least two nucleophilic reactive groups; and a crosslinking agent.

Group II is directed to a hydrogel composition, comprising a chitosan or derivative thereof having a molecular weight of 160 Dalton to 80,300 Dalton with a degree of deacetylation of 30% to 90% and at least two reactive nucleophilic groups, wherein the chitosan or derivative thereof is soluble in an aqueous solution having a basic pH; a multifunctional, polyethylene glycol polymer of a molecular weight of 200 Dalton to 100000 Dalton and comprising at least two nucleophilic reactive groups, and; a multifunctional, multi-armed crosslinker of polyethylene glycol having a molecular weight of 200 Dalton to 100000 Dalton and comprising at least two electrophilic reactive groups or multifunctional crosslinker of glutaraldehyde or derivative thereof comprising at least two aldehyde groups.

Group III is directed to a method of forming the hydrogel composition the hydrogel compositions of claims 1, 14, or 20, comprising; combining components of the hydrogel composition in a solution; allowing the solution to cure for a sufficient period of time to form a cured hydrogel composition; and fragmenting the cured hydrogel composition to form a fragmented hydrogel composition.

Group IV is directed to a method of reducing leakage across suture lines, anastomoses, or incisions; comprising; depositing the hydrogel composition of claims 1, 14, or 20 over at least a portion of the suture line, anastomoses, or incision; wherein the positioning of the hydrogel composition reduces leakage of fluid through the suture line, anastomoses or incision as compared to the absence of the hydrogel composition.

Group V is directed to a method of filling or closing vasculature or an aneurysm, comprising; depositing the hydrogel composition of claims 1, 14, or 20 within a targeted vasculature or aneurysm, wherein the depositing of the hydrogel fills or closes the vasculature or aneurysm.

Group VI is directed to a method of reducing bleeding of a wound, comprising; positioning the hydrogel composition of claims 1, 14, or 20 over at least a portion of the wound, wherein the positioning of the composition reduces or eliminates the flow of blood from the wound as compared to the absence of the hydrogel composition.

Group VII is directed to a method of managing a wound on a subject that provides for a moist environment that covers and protects exposed tissue, comprising; positioning the hydrogel composition of claims 1, 14, or 20 over at least a portion of the wound, wherein the positioning of the hydrogel composition provides a moist environment that at least partially covers and protects the exposed tissue as compared to the absence of the hydrogel composition.

Group VIII is directed to a method of applying the hydrogel composition of claims 1, 14, or 20 to a medical implant, comprising; depositing the hydrogel composition on a medical implant.

Group IX is directed to a method of forming a tissue scaffold, comprising; forming the hydrogel composition of claims 1, 14, or 20 into a tissue scaffold wherein the tissue scaffold optionally comprises mammalian cells.

Group X is directed to a method of delivering a therapeutic or palliative agent to a subject, comprising; administering to a subject the hydrogel composition of claims 1, 14, or 20 comprising a therapeutic or palliative agent, wherein the administering provides for delivery of the therapeutic or palliative agent to the subject.

Group XI is directed to a method of augmenting existing tissue with a hydrogel composition, comprising; administering the hydrogel composition of claims 1, 14, or 20 to a target tissue, wherein the administering provides for the augmentation of existing tissue as compared to the absence of the hydrogel composition.

Group XII is directed to a method of forming an energy barrier between a target tissue and an adjacent tissue, comprising; positioning the hydrogel composition of claims 1, 14, or 20 at a target area between a target tissue and an adjacent tissue, wherein the positioning of the hydrogel composition reduces transmission of energy from the target tissue to the adjacent tissue as compared to the absence of the hydrogel composition.

- see next sheet
INTERNATIONAL SEARCH REPORT

Continued from previous page:

Group XIII is directed to a method of filling a void in existing tissue, comprising: positioning the hydrogel composition of claims 1, 14, or 20 in a void in existing tissue wherein the position of the hydrogel composition at least partially occupies the void in the existing tissue.

Group XIV is directed to a method of adhering two or more tissues to each other, comprising: positioning the hydrogel composition of claims 1, 14, or 20 between at least two tissues wherein the positioning of the hydrogel composition provides for adhering the two tissue to each other as compared to the absence of the hydrogel composition.

Group XV is directed to a method of minimizing adhesion or friction between two or more tissues, comprising: positioning the hydrogel composition of claims 1, 14, or 20 between two or more tissues wherein the positioning of the composition minimizes adhesion or friction between the two or more tissues as compared to the absence of the hydrogel composition.

Group XVI is directed to a kit, comprising: the hydrogel composition of claims 1, 14, or 20, and a delivery device, wherein components of the hydrogel composition are provided in solution to form the hydrogel composition to enable delivery of the hydrogel composition to a target area or tissue.

The inventions listed as Groups I-XVI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Specifically, even though the inventions Groups I-XVI require the technical feature of a hydrogel composition comprising a polysaccharide substrate or derivative thereof having a molecular weight of 160 Dalton to 80,300 Dalton and comprising at least two reactive nucleophilic groups; a synthetic, hydrophilic polymer of a molecular weight of 200 Dalton to 100,000 Dalton and comprising at least two nucleophilic reactive groups; and a crosslinking agent, these technical features do not comprise a special technical feature as they do not make a contribution over the prior art in view of US 2007/0031498 A1 to Zong et al. (hereinafter "Zong"), which discloses a hydrogel composition (para [0002]), comprising a polysaccharide substrate or derivative thereof comprising at least two reactive nucleophilic groups (para [0056], [0070]), a synthetic, hydrophilic polymer of a molecular weight of 200 Dalton to 100,000 Dalton and comprising at least two nucleophilic reactive groups (para [0042], [0015]), and a crosslinking agent, (para [0041], [0070], [0080]) and further to US 4,532,334 A to Malette et al. (hereinafter 'Malette'), which discloses the polysaccharide having a molecular weight of 160 Dalton to 80,300 Dalton (table A; col 2, in 45) comprising at least two reactive nucleophilic groups (col 2, in 10-30 - formed by deacetylation). In addition, US 2007/0275246 A1 to Payne et al. (hereinafter 'Payne'), discloses a nucleophilic chitosan, which is an amine-rich polysaccharide derived by deacetylation used in forming hydrogels (para [0077], [0076]). Further, the crosslinker may comprise a polyethylene glycol having a molecular weight of 200 Dalton to 100,000 Dalton and comprising at least two electrophilic reactive groups (see Zong, para [0041], [0042], claim 5) or glutaraldehyde or derivative thereof comprising at least two aldehyde groups (para [0115], [0091]).

It would have been obvious to one skilled in the art to use the nucleophilic polysaccharide, as disclosed by Malette (formed by deacetylation, as disclosed by Payne), in forming the hydrogel, as disclosed by Zong, to optimize the properties of the reactants (see Payne para [0077], [0076]) for forming hydrogels useful in treating mammalian tissues (see Malette, abstract).

Groups I-XVI therefore lack unity under PCT Rule 13 because they do not share a same or corresponding special technical feature.